



La-Net

MED 618

PULMONOLOGY II



Course video is available on our app

lanetonline.com



la-NET | ONLINE LEARNING VIDEO PLATFORM FOR POST-SECONDARY & HIGHER INSTITUTION STUDENTS

Course code: MED 618

Course title: Pulmonology II

Course credit load: 2 Units

Series 1: Respiratory Tract Infections and Bacterial Pneumonias

- **Part 1.1: Upper Respiratory Tract Infections**
 - Sub Part 1.1.1: Pharyngitis and tonsillitis
 - Sub Part 1.1.2: Sinusitis and otitis media
 - Sub Part 1.1.3: Acute epiglottitis and laryngotracheobronchitis
- **Part 1.2: Approach to Pneumonia**
 - Sub Part 1.2.1: Pathophysiology and classification of pneumonia
 - Sub Part 1.2.2: Clinical presentation of pneumonia
 - Sub Part 1.2.3: Investigation and severity assessment of pneumonia
- **Part 1.3: Community-Acquired Bacterial Pneumonia**
 - Sub Part 1.3.1: Typical bacterial pneumonia
 - Sub Part 1.3.2: Atypical bacterial pneumonia
 - Sub Part 1.3.3: Management of community-acquired pneumonia
- **Part 1.4: Hospital-Acquired and Complicated Pneumonia**
 - Sub Part 1.4.1: Hospital-acquired and ventilator-associated pneumonia
 - Sub Part 1.4.2: Aspiration pneumonia
 - Sub Part 1.4.3: Complications of pneumonia

Introduction



This opening Series of **Pulmonology II** works through respiratory tract infection along its full anatomical span, from the genuinely common, generally benign upper respiratory tract infections through to the genuinely more serious lower respiratory tract infection of pneumonia, covered here in genuine depth given its status as one of the most clinically significant infectious conditions this whole course addresses.

The aim of this Series is to equip you with an understanding of upper respiratory tract infections including pharyngitis, sinusitis, otitis media, acute epiglottitis, and laryngotracheobronchitis, the pathophysiology, classification, presentation, investigation, and severity assessment of pneumonia, typical and atypical bacterial pneumonia and the management of community-acquired pneumonia, and hospital-acquired, ventilator-associated, aspiration pneumonia, and the complications of pneumonia.

This Series opens with **upper respiratory tract infections**, moves through the **approach to pneumonia** and **community-acquired bacterial pneumonia**, and closes with **hospital-acquired and complicated pneumonia**.

Series Learning Outcomes

At the end of this Series, you should be able to:

- **SLO 1.1:** describe upper respiratory tract infections including pharyngitis, sinusitis, and otitis media
- **SLO 1.2:** describe acute epiglottitis and laryngotracheobronchitis
- **SLO 1.3:** describe the pathophysiology, classification, and clinical presentation of pneumonia
- **SLO 1.4:** discuss the investigation and severity assessment of pneumonia
- **SLO 1.5:** describe typical and atypical bacterial pneumonia
- **SLO 1.6:** discuss the management of community-acquired pneumonia
- **SLO 1.7:** describe hospital-acquired, ventilator-associated, and aspiration pneumonia
- **SLO 1.8:** describe the complications of pneumonia



1.1 Upper Respiratory Tract Infections

1.1.1 pharyngitis and tonsillitis

A genuinely common presentation, viral more often than bacterial

Pharyngitis and **tonsillitis**, inflammation of the pharynx and tonsils respectively, most commonly result from viral infection, though **Group A Streptococcus** represents the most common significant bacterial cause, and distinguishing viral from bacterial aetiology, while genuinely challenging on clinical grounds alone, carries direct relevance to both symptomatic and antibiotic treatment decisions.

Clinical scoring systems, combining specific features including fever, tonsillar exudate, and absence of cough, help estimate the genuine likelihood of streptococcal infection and guide the decision to pursue further testing or empirical antibiotic treatment, and genuinely severe or persistent presentations warrant active consideration of the specific complications discussed further later in this Part.

Fill in the blank: Group A Streptococcus represents the most common significant bacterial cause of pharyngitis and _____.

1.1.2 sinusitis and otitis media

Infection of adjacent, connected air-filled spaces

Acute sinusitis, inflammation of the paranasal sinuses, most commonly follows a preceding viral upper respiratory tract infection, presenting with facial pain, nasal discharge, and congestion, and genuinely, the great majority of cases are viral or resolve spontaneously without requiring antibiotic treatment, with bacterial superinfection genuinely suggested by symptoms persisting or worsening beyond the typical expected viral course.

Acute otitis media, infection of the middle ear space, genuinely particularly common in young children given their anatomically shorter, more horizontal eustachian tube facilitating ascending infection from the nasopharynx, presents with ear pain and, on examination, a characteristically red, bulging tympanic membrane, and management similarly favours a genuinely conservative, watchful approach in the great majority of uncomplicated cases.

Fill in the blank: Acute otitis media is genuinely particularly common in young children given their anatomically shorter, more horizontal eustachian _____.



1.1.3 acute epiglottitis and laryngotracheobronchitis

Two genuinely important upper airway emergencies

Acute epiglottitis, genuinely severe inflammation and swelling of the epiglottis, is a genuine airway emergency given the significant risk of sudden, complete airway obstruction, presenting with rapid-onset fever, sore throat, drooling given painful swallowing, and a genuinely muffled voice, and any suspected case requires urgent, careful airway assessment and management by appropriately experienced clinicians given the risk that airway examination itself can precipitate complete obstruction.

Laryngotracheobronchitis, commonly termed croup, most commonly viral in young children, presents with a genuinely characteristic barking cough and inspiratory stridor, and, while generally considerably less immediately dangerous than epiglottitis already discussed, genuinely severe cases can still produce significant airway compromise requiring prompt recognition and appropriate treatment escalation.

Fill in the blank: Laryngotracheobronchitis, commonly termed croup, presents with a genuinely characteristic barking cough and inspiratory _____.

Examining the Throat for Tonsillitis



Figure 1.1: A clinician examining a patient's throat for exudative tonsillitis.



Pilot questions 1.1

1. Describe pharyngitis and tonsillitis and their most common causes. (Linked to SLO 1.1)
2. Describe acute sinusitis. (Linked to SLO 1.1)
3. Describe acute otitis media and why it is more common in young children. (Linked to SLO 1.1)
4. Describe acute epiglottitis and why it constitutes a genuine emergency. (Linked to SLO 1.2)
5. Describe laryngotracheobronchitis. (Linked to SLO 1.2)

1.2 Approach to Pneumonia

1.2.1 pathophysiology and classification of pneumonia

Infection reaching the genuinely essential gas-exchanging tissue

Pneumonia, infection of the lung parenchyma itself, results from a pathogen genuinely overwhelming the respiratory tract's normal defence mechanisms, producing inflammatory exudate within the alveoli that directly impairs normal gas exchange, and this genuine impairment of the lung's fundamental gas-exchanging function directly underlies the specific clinical presentation discussed in the following sub-Part of this Part.

Pneumonia is classified by genuine setting of acquisition, **community-acquired**, discussed in depth in Part 1.3, **hospital-acquired**, and **aspiration pneumonia**, both discussed further in Part 1.4, a classification framework carrying genuinely significant practical value since the specific likely causative organisms, and therefore the most appropriate empirical treatment approach, genuinely differ considerably across these distinct categories.

Fill in the blank: Pneumonia produces inflammatory exudate within the alveoli that directly impairs normal gas _____.



1.2.2 clinical presentation of pneumonia

A genuinely characteristic combination of respiratory and systemic features

Pneumonia presents with cough, often productive of purulent sputum, breathlessness, and pleuritic chest pain, alongside systemic features including fever and malaise, and examination findings, including reduced air entry, bronchial breathing, and coarse crackles over the affected area, reflect the underlying consolidation, the alveolar filling with inflammatory exudate already discussed in the previous sub-Part.

Atypical presentation, particularly in older patients, already discussed in relation to atypical infection presentation in an earlier course of this programme, can present with confusion or non-specific functional decline rather than the classic respiratory symptom pattern already discussed, underlining why pneumonia should be actively considered in this specific patient population presenting with unexplained deterioration, rather than relying on classic symptoms alone.

Fill in the blank: Atypical pneumonia presentation in older patients can include confusion or non-specific functional decline rather than the classic _____ symptom pattern.

1.2.3 investigation and severity assessment of pneumonia

Confirming the diagnosis and, genuinely essentially, grading severity

Chest radiography, demonstrating the characteristic consolidation already discussed, confirms the diagnosis, alongside inflammatory markers and, where genuinely indicated, blood and sputum cultures to identify the specific causative organism and guide targeted treatment once results become available, following the same empirical-then-targeted treatment sequence already established for infection generally in an earlier course of this programme.

Structured severity assessment, using validated scoring tools combining specific clinical and laboratory parameters including confusion, respiratory rate, blood pressure, and age, genuinely, directly guides the decision between outpatient management, hospital admission, and, for the most severe cases, intensive care assessment, and this structured, criteria-based approach genuinely improves consistency of this specific, important clinical decision.

Fill in the blank: Structured severity assessment genuinely, directly guides the decision between outpatient management, hospital admission, and intensive care _____.

Table 1.1: Components of a structured pneumonia severity assessment score

Parameter	Feature assessed	Genuine clinical relevance
-----------	------------------	----------------------------



Confusion	New disorientation	Reflects severity of systemic illness
Respiratory rate	Elevated breathing rate	Reflects degree of respiratory compromise
Blood pressure	Hypotension	Reflects haemodynamic compromise

Pilot questions 1.2

1. Describe the pathophysiology of pneumonia. (Linked to SLO 1.3)
2. Describe how pneumonia is classified by setting of acquisition. (Linked to SLO 1.3)
3. Describe the classic clinical presentation of pneumonia. (Linked to SLO 1.3)
4. Explain why atypical presentation in older patients genuinely matters. (Linked to SLO 1.3)
5. Describe the role of structured severity assessment in pneumonia management. (Linked to SLO 1.4)

1.3 Community-Acquired Bacterial Pneumonia

1.3.1 typical bacterial pneumonia

The most common cause, with a genuinely classic presentation

Streptococcus pneumoniae, the most common cause of community-acquired bacterial pneumonia overall, produces the genuinely classic pneumonia presentation already discussed in the previous Part, and other **typical bacterial pathogens**, including *Haemophilus influenzae*, particularly in patients with underlying chronic respiratory disease already discussed elsewhere in this course, complete this genuinely common, classically presenting category of community-acquired pneumonia.

Sputum Gram stain and culture, where genuinely obtainable and of adequate quality, can help identify the specific typical bacterial pathogen responsible, though genuinely, empirical antibiotic treatment covering the most likely causative organisms, discussed further later in this Part, is typically initiated before these results become available given the genuine time this specific investigation requires.



Fill in the blank: Streptococcus pneumoniae is the most common cause of community-acquired bacterial _____ overall.

1.3.2 atypical bacterial pneumonia

A genuinely distinct group requiring specific antibiotic coverage

Atypical bacterial pathogens, including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila, produce a genuinely somewhat different clinical presentation compared with typical pneumonia already discussed, often with a more gradual onset and prominent extrapulmonary features, and, genuinely importantly, these organisms are not detectable by standard Gram stain given their genuinely distinct cell wall structure or absence of a genuine cell wall entirely.

Legionella pneumophila specifically, associated with exposure to contaminated water sources, can produce genuinely severe pneumonia alongside specific extrapulmonary features including gastrointestinal symptoms and confusion, and this genuinely distinct pathogen category, given its resistance to standard antibiotic classes effective against typical bacteria, directly explains why empirical community-acquired pneumonia treatment genuinely requires coverage addressing both typical and atypical organisms simultaneously.

Fill in the blank: Atypical bacterial pathogens are not detectable by standard Gram stain given their distinct or absent cell _____.

1.3.3 management of community-acquired pneumonia

Empirical antibiotics genuinely covering both typical and atypical organisms

Empirical antibiotic therapy, genuinely selected to provide coverage against both typical and atypical pathogens already discussed, forms the mainstay of community-acquired pneumonia management, with the specific antibiotic choice and route, oral or intravenous, genuinely guided by the structured severity assessment already established in the previous Part, matching treatment intensity to genuine disease severity.

Supportive care, including adequate oxygenation and fluid management, alongside prompt treatment escalation where genuine clinical deterioration occurs despite initial treatment, closes this Part's coverage of community-acquired pneumonia management, and this genuinely structured, severity-matched treatment approach directly reflects the same individualised clinical decision-making philosophy already emphasised consistently throughout this whole course.

Fill in the blank: Antibiotic route, oral or intravenous, is genuinely guided by the structured severity assessment, matching treatment intensity to genuine disease _____.



Chest Auscultation



Figure 1.2: A clinician auscultating a patient's chest for characteristic pneumonia findings.

Pilot questions 1.3

1. Describe typical bacterial pneumonia and its most common causative organism. (Linked to SLO 1.5)
2. List common atypical bacterial pathogens. (Linked to SLO 1.5)
3. Describe *Legionella pneumophila* and its specific extrapulmonary features. (Linked to SLO 1.5)
4. Explain why standard Gram stain does not detect atypical organisms. (Linked to SLO 1.5)
5. Describe the general management approach to community-acquired pneumonia. (Linked to SLO 1.6)



1.4 Hospital-Acquired and Complicated Pneumonia

1.4.1 hospital-acquired and ventilator-associated pneumonia

A genuinely distinct organism profile reflecting the healthcare environment

Hospital-acquired pneumonia, genuinely defined as pneumonia developing forty-eight hours or more after hospital admission, and **ventilator-associated pneumonia**, developing in patients receiving mechanical ventilation, involve a genuinely, considerably different range of causative organisms compared with community-acquired pneumonia already discussed, including organisms with greater antibiotic resistance given the healthcare environment's specific microbial ecology.

This genuinely distinct organism profile directly requires a genuinely different empirical antibiotic approach compared with community-acquired pneumonia, typically broader-spectrum coverage reflecting the increased resistance risk already discussed, and recognising this specific classification distinction genuinely matters given how directly it shapes the most appropriate initial empirical treatment choice before culture results become available.

Fill in the blank: Hospital-acquired pneumonia is genuinely defined as pneumonia developing forty-eight _____ or more after hospital admission.

1.4.2 aspiration pneumonia

A genuinely distinct mechanism, already introduced elsewhere in this programme

Aspiration pneumonia, already introduced in principle in an earlier course of this programme in relation to anaerobic infection, results from aspiration of oropharyngeal or gastric contents into the lower respiratory tract, particularly in patients with impaired swallowing or reduced consciousness, and characteristically involves the anaerobic organisms already discussed extensively in that earlier course given their genuine density within normal oropharyngeal flora.

Risk factor identification, including stroke, already discussed in an earlier course of this programme, reduced consciousness, and specific swallowing disorders, genuinely matters clinically, since addressing the underlying predisposing factor, where genuinely feasible, alongside the acute pneumonia treatment itself, directly reduces the risk of genuinely recurrent aspiration pneumonia episodes in this specific, vulnerable patient population.

Fill in the blank: Aspiration pneumonia characteristically involves the anaerobic organisms given their genuine density within normal oropharyngeal _____.



1.4.3 complications of pneumonia

Genuine local and systemic consequences requiring active vigilance

Parapneumonic effusion, fluid accumulation within the pleural space adjacent to the pneumonia, and, where this fluid becomes genuinely infected, **empyema**, requires active consideration and, where genuinely significant, drainage alongside continued antibiotic treatment, and **lung abscess**, already discussed in principle in relation to anaerobic infection in an earlier course of this programme, represent genuinely important local complications this Part aims to establish confident recognition of.

Sepsis, already discussed extensively in an earlier course of this programme, represents the genuinely most serious systemic complication pneumonia can produce, and active, structured screening for this specific complication, following the same principles already established in that earlier coverage, forms an essential, ongoing component of comprehensive pneumonia management throughout the patient's treatment course, closing this Series's coverage of respiratory tract infection.

Fill in the blank: Active, structured screening for sepsis forms an essential, ongoing component of comprehensive pneumonia management throughout the treatment _____.

Table 1.2: Comparing community-acquired, hospital-acquired, and aspiration pneumonia

Category	Typical organism profile	Key clinical consideration
Community-acquired	Streptococcus pneumoniae, atypical organisms	Structured severity assessment guides treatment
Hospital-acquired	More resistant organisms	Broader-spectrum empirical antibiotics
Aspiration	Anaerobic organisms	Identify and address underlying risk factor

Pilot questions 1.4

1. Describe hospital-acquired pneumonia and its genuinely distinct organism profile. (Linked to SLO 1.7)
2. Describe ventilator-associated pneumonia. (Linked to SLO 1.7)
3. Describe aspiration pneumonia and its typical causative organisms. (Linked to SLO 1.7)
4. List complications of pneumonia. (Linked to SLO 1.8)
5. Describe parapneumonic effusion and empyema. (Linked to SLO 1.8)



Series Summary

This opening Series worked through respiratory tract infection, from upper airway infection through to bacterial pneumonia. Part 1.1 covered pharyngitis, sinusitis, otitis media, epiglottitis, and laryngotracheobronchitis, while Part 1.2 turned to the pathophysiology, presentation, and severity assessment of pneumonia. Part 1.3 covered community-acquired bacterial pneumonia, and Part 1.4 closed with hospital-acquired and complicated pneumonia.

You should now be able to describe and manage respiratory tract infections and bacterial pneumonia across all four Parts of this Series, meeting the outcomes set for this Series. Series 2 turns next to tuberculosis: pulmonary and extrapulmonary disease.

Glossary of Terms

- **Acute epiglottitis:** severe inflammation and swelling of the epiglottis, a genuine airway emergency.
- **Aspiration pneumonia:** pneumonia from aspiration of oropharyngeal or gastric contents.
- **Atypical bacterial pneumonia:** pneumonia from organisms lacking a standard bacterial cell wall structure.
- **Community-acquired pneumonia:** pneumonia acquired outside the healthcare setting.
- **Consolidation:** alveolar filling with inflammatory exudate characteristic of pneumonia.
- **Empyema:** infected fluid accumulation within the pleural space.
- **Hospital-acquired pneumonia:** pneumonia developing forty-eight hours or more after hospital admission.
- **Laryngotracheobronchitis:** croup, presenting with a barking cough and inspiratory stridor.
- **Legionella pneumophila:** an atypical pathogen associated with contaminated water exposure.
- **Parapneumonic effusion:** fluid accumulation within the pleural space adjacent to pneumonia.
- **Streptococcus pneumoniae:** the most common cause of community-acquired bacterial pneumonia.
- **Ventilator-associated pneumonia:** pneumonia developing in patients receiving mechanical ventilation.

Concept Check Questions [Series 1]

Objective questions



1. Group A Streptococcus represents the most common significant bacterial cause of pharyngitis and _____. (Linked to SLO 1.1)
2. Laryngotracheobronchitis, commonly termed croup, presents with a genuinely characteristic barking cough and inspiratory _____. (Linked to SLO 1.2)
3. Pneumonia produces inflammatory exudate within the alveoli that directly impairs normal gas _____. (Linked to SLO 1.3)
4. Atypical bacterial pathogens are not detectable by standard Gram stain given their distinct or absent cell _____. (Linked to SLO 1.5)
5. Hospital-acquired pneumonia is genuinely defined as pneumonia developing forty-eight _____ or more after hospital admission. (Linked to SLO 1.7)

Short-answer questions

6. Describe acute epiglottitis and why it constitutes a genuine emergency. (Linked to SLO 1.2)
7. Describe the classic clinical presentation of pneumonia. (Linked to SLO 1.3)
8. Describe Legionella pneumophila and its specific extrapulmonary features. (Linked to SLO 1.5)
9. Describe aspiration pneumonia and its typical causative organisms. (Linked to SLO 1.7)
10. Describe parapneumonic effusion and empyema. (Linked to SLO 1.8)

Long-answer questions

11. Discuss upper respiratory tract infections, including acute epiglottitis and laryngotracheobronchitis. (Linked to SLO 1.1, 1.2)
12. Describe the pathophysiology, classification, presentation, investigation, and severity assessment of pneumonia. (Linked to SLO 1.3, 1.4)
13. Discuss typical and atypical bacterial pneumonia and the management of community-acquired pneumonia. (Linked to SLO 1.5, 1.6)
14. Describe hospital-acquired, ventilator-associated, and aspiration pneumonia. (Linked to SLO 1.7)
15. Discuss the complications of pneumonia. (Linked to SLO 1.8)

Answers to Concept Check Questions [Series 1]

Objective questions

1. Tonsillitis.
2. Stridor.
3. Exchange.



4. Wall.
5. Hours.

Short-answer questions

6. Acute epiglottitis is severe epiglottic swelling risking sudden, complete airway obstruction.
7. Presentation includes productive cough, breathlessness, pleuritic chest pain, and systemic fever.
8. Legionella is associated with contaminated water and produces gastrointestinal symptoms and confusion.
9. Aspiration pneumonia results from aspirated oropharyngeal contents, typically involving anaerobic organisms.
10. Parapneumonic effusion is fluid adjacent to pneumonia; empyema is infected fluid requiring drainage.

Long-answer questions

11. **Basic response:** Pharyngitis, sinusitis, and otitis media are typically viral and generally self-limiting; acute epiglottitis is a genuine airway emergency; laryngotracheobronchitis presents with barking cough and stridor.

Value-added response: A value-added response notes that suspected epiglottitis requires careful, expert airway assessment given the risk examination itself can precipitate obstruction.

12. **Basic response:** Pneumonia is lung parenchymal infection producing alveolar consolidation, classified by acquisition setting; presentation includes cough, fever, and pleuritic pain; investigation uses chest radiography, with structured severity assessment guiding treatment location.

Value-added response: A value-added response notes that older patients can present atypically with confusion rather than classic respiratory symptoms.

13. **Basic response:** Streptococcus pneumoniae is the most common typical cause; atypical pathogens include Mycoplasma, Chlamydia, and Legionella, requiring specific antibiotic coverage; management uses empirical antibiotics covering both categories, guided by severity.

Value-added response: A value-added response notes that atypical organisms are not detectable by standard Gram stain given their distinct cell wall structure.



14. **Basic response:** Hospital-acquired pneumonia develops after forty-eight hours in hospital with more resistant organisms; ventilator-associated pneumonia occurs in mechanically ventilated patients; aspiration pneumonia involves anaerobic organisms from aspirated contents.

Value-added response: A value-added response notes that identifying and addressing the underlying aspiration risk factor reduces recurrence.

15. **Basic response:** Complications include parapneumonic effusion, empyema, lung abscess, and sepsis, requiring active, structured screening throughout treatment.

Value-added response: A value-added response notes that sepsis represents the most serious systemic complication pneumonia can produce.

Answers to Pilot Questions [Series 1]

Part 1.1

1. Pharyngitis and tonsillitis are most commonly viral, with Group A Streptococcus the most common bacterial cause.
2. Acute sinusitis is paranasal sinus inflammation, most commonly following a preceding viral infection.
3. Otitis media is more common in children given their shorter, more horizontal eustachian tube.
4. Epiglottitis risks sudden, complete airway obstruction, requiring careful, expert airway management.
5. Laryngotracheobronchitis, or croup, presents with a barking cough and inspiratory stridor.

Part 1.2

1. Pneumonia results from a pathogen overwhelming defences, producing alveolar inflammatory exudate.
2. Pneumonia is classified as community-acquired, hospital-acquired, or aspiration pneumonia.
3. Presentation includes productive cough, breathlessness, pleuritic pain, and systemic features.



4. Older patients can present with confusion rather than classic symptoms, requiring active consideration.
5. Severity assessment guides the decision between outpatient management, admission, and intensive care.

Part 1.3

1. Typical bacterial pneumonia is most commonly caused by *Streptococcus pneumoniae*.
2. Atypical pathogens include *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila*.
3. *Legionella* is associated with contaminated water, producing gastrointestinal symptoms and confusion.
4. Atypical organisms have a distinct or absent cell wall structure, undetectable by standard Gram stain.
5. Management uses empirical antibiotics covering typical and atypical organisms, guided by severity assessment.

Part 1.4

1. Hospital-acquired pneumonia develops after forty-eight hours in hospital, involving more resistant organisms.
2. Ventilator-associated pneumonia develops in patients receiving mechanical ventilation.
3. Aspiration pneumonia results from aspirated contents, typically involving anaerobic organisms.
4. Complications include parapneumonic effusion, empyema, lung abscess, and sepsis.
5. Parapneumonic effusion is adjacent fluid accumulation; empyema is infected fluid requiring drainage.

References and Attributions [Series 1]

- Kumar, P., & Clark, M. (2020). *Kumar and Clark's Clinical Medicine* (10th ed.). Elsevier.
- Mandell, G. L., Bennett, J. E., & Dolin, R. (2019). *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases* (9th ed.). Elsevier.
- British Thoracic Society (2023). *Guidelines for the Management of Community-Acquired Pneumonia in Adults*. Thorax.
- National Institute for Health and Care Excellence (2019). *Pneumonia in Adults: Diagnosis and Management* (CG191). NICE.



Figures, Plates, Tables, and Boxes

- Figure 1.1: A clinician examining a patient's throat for exudative tonsillitis. AI-generated using the prompt: "Create a realistic clinical illustration titled Examining the Throat for Tonsillitis, showing a clinician using a tongue depressor and pen torch to examine a seated patient's open mouth and throat, clinical examination room setting. Clean clinical illustration style, no text."
- Table 1.1: Components of a structured pneumonia severity assessment score. AI-generated using the prompt: "Create a clean reference table titled Components of a Structured Pneumonia Severity Assessment Score, listing parameter, feature assessed, and genuine clinical relevance. Simple clinical reference table style with outside border."
- Figure 1.2: A clinician auscultating a patient's chest for characteristic pneumonia findings. AI-generated using the prompt: "Create a realistic clinical illustration titled Chest Auscultation, showing a clinician using a stethoscope to listen to a seated patient's chest and back, clinical examination room setting. Clean clinical illustration style, no text."
- Table 1.2: Comparing community-acquired, hospital-acquired, and aspiration pneumonia. AI-generated using the prompt: "Create a clean reference table titled Comparing Community-Acquired, Hospital-Acquired, and Aspiration Pneumonia, listing category, typical organism profile, and key clinical consideration. Simple clinical reference table style with outside border."



Course code: MED 618

Course title: Pulmonology II

Course credit load: 2 Units

Series 2: Tuberculosis: Pulmonary and Extrapulmonary Disease

- **Part 2.1: Microbiology and Pathogenesis of Tuberculosis**
 - Sub Part 2.1.1: Microbiology of Mycobacterium tuberculosis
 - Sub Part 2.1.2: Transmission and primary infection
 - Sub Part 2.1.3: Latent tuberculosis infection and reactivation
- **Part 2.2: Pulmonary Tuberculosis**
 - Sub Part 2.2.1: Clinical presentation of pulmonary tuberculosis
 - Sub Part 2.2.2: Investigation and diagnosis of pulmonary tuberculosis
 - Sub Part 2.2.3: Drug-resistant tuberculosis
- **Part 2.3: Extrapulmonary Tuberculosis**
 - Sub Part 2.3.1: Tuberculous lymphadenitis and pleural disease
 - Sub Part 2.3.2: Tuberculous meningitis and central nervous system disease
 - Sub Part 2.3.3: Skeletal, genitourinary, and other extrapulmonary tuberculosis
- **Part 2.4: Management and Prevention of Tuberculosis**
 - Sub Part 2.4.1: Principles of antituberculous therapy
 - Sub Part 2.4.2: Monitoring and complications of treatment
 - Sub Part 2.4.3: Prevention and public health control of tuberculosis

Introduction

This Series turns to **tuberculosis**, a genuinely major global infectious disease demanding structured understanding across its full clinical spectrum, from the initial microbiology and



pathogenesis, through pulmonary disease, the most commonly encountered clinical presentation, to the genuinely wide range of extrapulmonary sites this organism can affect, before closing with the specific management and public health considerations tuberculosis genuinely requires.

The aim of this Series is to equip you with an understanding of the microbiology, transmission, latent infection, and reactivation of *Mycobacterium tuberculosis*, the presentation, investigation, diagnosis, and drug resistance of pulmonary tuberculosis, extrapulmonary tuberculosis including lymphadenitis, pleural, meningeal, skeletal, and genitourinary disease, and the principles, monitoring, complications, prevention, and public health control of antituberculous therapy.

This Series opens with the **microbiology and pathogenesis of tuberculosis**, moves through **pulmonary tuberculosis** and **extrapulmonary tuberculosis**, and closes with **management and prevention of tuberculosis**.

Series Learning Outcomes

At the end of this Series, you should be able to:

- **SLO 2.1:** describe the microbiology of *Mycobacterium tuberculosis* and its transmission
- **SLO 2.2:** describe latent tuberculosis infection and reactivation
- **SLO 2.3:** describe the clinical presentation of pulmonary tuberculosis
- **SLO 2.4:** discuss the investigation, diagnosis, and drug resistance of pulmonary tuberculosis
- **SLO 2.5:** describe tuberculous lymphadenitis and pleural disease
- **SLO 2.6:** describe skeletal, genitourinary, and other extrapulmonary tuberculosis
- **SLO 2.7:** describe the principles, monitoring, and complications of antituberculous therapy
- **SLO 2.8:** discuss the prevention and public health control of tuberculosis

2.1 Microbiology and Pathogenesis of Tuberculosis

2.1.1 microbiology of mycobacterium tuberculosis

A genuinely slow-growing organism with a distinctive cell wall

Mycobacterium tuberculosis, genuinely distinct from the non-tuberculous mycobacteria already discussed in an earlier course of this programme, possesses a genuinely unique, lipid-rich cell wall directly conferring its characteristic acid-fast staining property, resistance to standard



Gram staining, and genuinely slow growth rate requiring considerably longer culture incubation than most bacteria already discussed elsewhere in this programme.

This genuinely distinctive cell wall also directly contributes to the organism's capacity for intracellular survival within host macrophages, already introduced in principle in relation to microbial evasion of host defence in an earlier course of this programme, a specific survival strategy directly underlying the chronic, often genuinely prolonged natural history tuberculosis characteristically demonstrates.

Fill in the blank: The lipid-rich cell wall of *Mycobacterium tuberculosis* directly confers its characteristic acid-fast _____ property.

2.1.2 transmission and primary infection

Airborne spread, and a genuinely characteristic initial host response

Transmission occurs through inhalation of genuinely small, airborne droplet nuclei, typically requiring prolonged, close contact with an infectious individual for genuine transmission to occur, and **primary infection**, the host's initial encounter with the organism, triggers a genuinely characteristic granulomatous immune response, forming the **Ghon focus**, a localised area of infection, and associated lymph node involvement together termed the Ghon complex.

In the great majority of genuinely immunocompetent individuals, this initial primary infection is genuinely successfully contained by the host immune response already discussed, without producing clinically apparent active disease, and this genuinely successful containment, rather than complete organism elimination, directly explains the latent infection state discussed in the following sub-Part of this Part.

Fill in the blank: Transmission occurs through inhalation of genuinely small, airborne droplet _____.

2.1.3 latent tuberculosis infection and reactivation

A genuinely dormant, but not eliminated, infection state

Latent tuberculosis infection, the genuinely dormant state following successful containment of primary infection already discussed, is genuinely asymptomatic and non-infectious, though the organism remains genuinely viable within the host, capable of **reactivation** if host immune defence subsequently becomes genuinely compromised, whether from ageing, immunosuppressive medication already discussed in principle elsewhere in this course, or specific conditions including HIV infection.



Reactivation produces active disease, most commonly pulmonary tuberculosis discussed in the following Part of this Series, and the genuinely significant lifetime risk of reactivation this latent infection state carries directly underlies the rationale for latent tuberculosis infection screening and preventive treatment in appropriately selected, higher-risk individuals, discussed further later in this Series.

Fill in the blank: Reactivation of latent tuberculosis infection occurs if host immune defence subsequently becomes genuinely _____.




Figure 2.1: A labelled diagram of granuloma formation surrounding *Mycobacterium tuberculosis*.

Pilot questions 2.1

- Describe the distinctive cell wall of *Mycobacterium tuberculosis*. (Linked to SLO 2.1)
- Describe how tuberculosis is transmitted. (Linked to SLO 2.1)
- Describe the Ghon complex. (Linked to SLO 2.1)
- Describe latent tuberculosis infection. (Linked to SLO 2.2)
- Describe reactivation and its recognised triggers. (Linked to SLO 2.2)



2.2 Pulmonary Tuberculosis

2.2.1 clinical presentation of pulmonary tuberculosis

A genuinely chronic, insidious presentation

Pulmonary tuberculosis, the most common clinical manifestation of active tuberculosis, presents with chronic cough, typically persisting beyond two to three weeks, alongside haemoptysis, weight loss, night sweats, and fever, a genuinely characteristic, chronic, insidious symptom pattern developing gradually over weeks to months rather than the more acute presentation characteristic of the bacterial pneumonia already discussed in the previous Series of this course.

This genuinely chronic symptom pattern, particularly persistent cough beyond the typical duration expected for a self-limiting respiratory infection, should actively prompt consideration of pulmonary tuberculosis, particularly in patients with recognised risk factors including relevant geographic origin or exposure history, immunocompromise already discussed earlier in this Series, or close contact with a confirmed case.

Fill in the blank: Pulmonary tuberculosis presents with chronic cough, typically persisting beyond two to three _____.

2.2.2 investigation and diagnosis of pulmonary tuberculosis

Combining imaging, microbiological confirmation, and rapid molecular testing

Chest radiography, demonstrating characteristic findings including upper lobe infiltrate and, in more advanced disease, cavitation, supports the diagnosis, and **sputum microscopy for acid-fast bacilli**, already directly reflecting the distinctive cell wall staining property discussed earlier in this Series, provides genuinely rapid supportive evidence, though genuinely, culture, requiring the considerably longer incubation already discussed, remains necessary for definitive confirmation and drug susceptibility testing.

Molecular diagnostic techniques, directly detecting *Mycobacterium tuberculosis* genetic material, offer genuinely considerably faster results than traditional culture, and, genuinely importantly, several of these specific molecular tests can simultaneously detect resistance to key first-line antituberculous drugs, discussed further in the following sub-Part, providing genuinely valuable, rapid information directly shaping the initial treatment approach.

Fill in the blank: Molecular diagnostic techniques can simultaneously detect resistance to key first-line antituberculous _____.



2.2.3 drug-resistant tuberculosis

A genuinely growing, significant global challenge

Drug-resistant tuberculosis, resulting from genetic mutation conferring resistance to specific antituberculous agents, is classified according to the specific pattern of resistance, **multidrug-resistant tuberculosis**, resistance to at least the two most important first-line agents, and **extensively drug-resistant tuberculosis**, resistance additionally extending to key second-line agents, each representing genuinely progressively more challenging treatment scenarios.

Inadequate or interrupted treatment, genuinely allowing selection of resistant organism subpopulations, represents a genuinely major driver of drug resistance development, directly underlining why the treatment adherence support discussed further later in this Series genuinely matters, and drug-resistant tuberculosis requires genuinely prolonged, more complex treatment regimens carrying a considerably less favourable overall prognosis compared with fully drug-susceptible disease.

Fill in the blank: Inadequate or interrupted treatment represents a genuinely major driver of drug _____ development.

Table 2.1: Comparing latent and active pulmonary tuberculosis

Feature	Latent infection	Active pulmonary disease
Symptoms	Absent	Chronic cough, weight loss, night sweats
Infectiousness	Non-infectious	Genuinely infectious
Chest radiograph	Typically normal	Infiltrate, possible cavitation

Pilot questions 2.2

1. Describe the classic clinical presentation of pulmonary tuberculosis. (Linked to SLO 2.3)
2. Describe chest radiographic findings suggestive of pulmonary tuberculosis. (Linked to SLO 2.4)
3. Describe sputum microscopy for acid-fast bacilli. (Linked to SLO 2.4)
4. Distinguish multidrug-resistant from extensively drug-resistant tuberculosis. (Linked to SLO 2.4)
5. Explain why inadequate or interrupted treatment drives drug resistance development. (Linked to SLO 2.4)



2.3 Extrapulmonary Tuberculosis

2.3.1 tuberculous lymphadenitis and pleural disease

Two genuinely common extrapulmonary presentations

Tuberculous lymphadenitis, commonly termed scrofula when affecting the cervical lymph nodes, presents with genuinely painless, progressive lymph node enlargement, sometimes eventually discharging through the overlying skin if left inadequately treated, and represents one of the genuinely most common extrapulmonary tuberculosis presentations, with tissue biopsy typically required for confident diagnostic confirmation.

Tuberculous pleural disease, presenting with pleural effusion and associated pleuritic chest pain and breathlessness, results from a genuine hypersensitivity reaction to tuberculous antigens within the pleural space, and pleural fluid analysis, alongside pleural biopsy in genuinely diagnostically uncertain cases, confirms the diagnosis, given the genuinely relatively low sensitivity of pleural fluid culture alone for this specific extrapulmonary presentation.

Fill in the blank: Tuberculous lymphadenitis is commonly termed scrofula when affecting the _____ lymph nodes.

2.3.2 tuberculous meningitis and central nervous system disease

A genuinely serious presentation, already introduced elsewhere in this programme

Tuberculous meningitis, already discussed in genuine depth in an earlier course of this programme covering neurology, remains a genuinely important extrapulmonary tuberculosis presentation to actively recognise within this Series's broader coverage, presenting with the genuinely insidious onset already established in that earlier discussion, and carrying genuine, significant risk of permanent neurological damage or death if treatment is delayed.

This Series does not repeat the full detail already covered elsewhere in this programme regarding tuberculous meningitis specifically, but genuinely reinforces the essential principle that central nervous system tuberculosis, given its genuine severity, warrants the same urgent recognition and empirical treatment initiation already established for this specific condition, without awaiting complete microbiological confirmation given the genuine time-critical nature of appropriate treatment.



Fill in the blank: Central nervous system tuberculosis warrants urgent recognition and empirical treatment initiation without awaiting complete microbiological _____.

2.3.3 skeletal, genitourinary, and other extrapulmonary tuberculosis

A genuinely wide-ranging pattern reflecting haematogenous spread

Skeletal tuberculosis, most classically affecting the spine, termed Pott's disease, presents with back pain and, in advanced cases, spinal deformity and neurological compromise from vertebral collapse, and **genitourinary tuberculosis**, affecting the kidneys and genital tract, can present with sterile pyuria, urinary white cells without a positive standard bacterial culture, alongside more specific genitourinary symptoms.

Miliary tuberculosis, genuinely widespread haematogenous dissemination producing numerous small, characteristic lesions across multiple organs, represents a genuinely severe presentation particularly, though not exclusively, occurring in immunocompromised patients already discussed earlier in this Series, and this genuinely wide-ranging extrapulmonary spectrum, closing this Part's coverage, underlines why tuberculosis genuinely demands active consideration across a genuinely broad range of clinical presentations.

Fill in the blank: Sterile pyuria is urinary white cells without a positive standard bacterial _____.

Cervical Lymphadenopathy in Tuberculous Lymphadenitis



Figure 2.2: Enlarged cervical lymph nodes characteristic of tuberculous lymphadenitis.



Pilot questions 2.3

1. Describe tuberculous lymphadenitis. (Linked to SLO 2.5)
2. Describe tuberculous pleural disease. (Linked to SLO 2.5)
3. Describe Pott's disease. (Linked to SLO 2.6)
4. Describe genitourinary tuberculosis and sterile pyuria. (Linked to SLO 2.6)
5. Describe miliary tuberculosis. (Linked to SLO 2.6)

2.4 Management and Prevention of Tuberculosis

2.4.1 principles of antituberculous therapy

Multiple agents, a genuinely prolonged treatment course

Combination antituberculous therapy, using multiple agents simultaneously, genuinely reduces the risk of resistance emerging during treatment, discussed earlier in this Series, and standard first-line treatment typically combines four agents during an initial intensive phase, before continuing with a reduced regimen during a genuinely prolonged continuation phase, with total treatment duration typically extending across several months for standard drug-susceptible pulmonary disease.

Directly observed therapy, genuinely supervised medication administration ensuring reliable adherence, is particularly recommended for patients at genuine risk of treatment non-adherence, directly addressing the resistance risk already discussed earlier in this Series, and this specific, structured adherence support approach reflects the genuine, significant public health importance of completing tuberculosis treatment fully and reliably.

Fill in the blank: Standard first-line antituberculous treatment typically combines four agents during an initial intensive _____.

2.4.2 monitoring and complications of treatment

Genuine treatment risks requiring active surveillance

Hepatotoxicity, a genuinely recognised risk of several first-line antituberculous agents, requires regular liver function monitoring throughout treatment, particularly during the initial weeks



when this specific risk is genuinely greatest, and patients require clear counselling regarding symptoms warranting urgent medical review, mirroring the same structured medication monitoring principle already emphasised for other medications throughout this course.

Visual disturbance, a specific, recognised side effect of one particular first-line agent requiring active screening given its genuine, potentially irreversible nature if unrecognised, and peripheral neuropathy, genuinely preventable through co-administration of a specific supplementary vitamin, complete this Part's coverage of the specific, structured monitoring requirements comprehensive antituberculous therapy genuinely demands.

Fill in the blank: Visual disturbance requires active screening given its genuine, potentially _____ nature if unrecognised.

2.4.3 prevention and public health control of tuberculosis

A genuinely essential public health, alongside individual clinical, priority

Contact tracing, systematically identifying and screening individuals who have had genuine, close contact with a confirmed infectious case, allows early identification of both latent infection and active disease among contacts, and **latent tuberculosis infection treatment**, already introduced earlier in this Series, in appropriately selected, higher-risk contacts genuinely reduces the future risk of reactivation and onward transmission.

Bacillus Calmette-Guérin vaccination, offering partial protection, particularly genuinely valuable against severe disseminated disease in young children, alongside comprehensive infection control measures in healthcare and congregate settings, complete this genuinely comprehensive public health approach to tuberculosis control, closing this Series, and this whole course's coverage of respiratory tract infection, on the theme of prevention alongside treatment that has run consistently throughout this programme.

Fill in the blank: Bacillus Calmette-Guérin vaccination is particularly genuinely valuable against severe _____ disease in young children.

Table 2.2: Comparing first-line antituberculous drugs and their genuinely notable side effects

Drug	Genuinely notable side effect	Monitoring requirement
Isoniazid	Peripheral neuropathy	Co-administer pyridoxine
Rifampicin	Hepatotoxicity, orange discolouration of secretions	Liver function monitoring



Ethambutol	Visual disturbance	Regular visual acuity screening
------------	--------------------	---------------------------------

Pilot questions 2.4

1. Describe the standard structure of first-line antituberculous therapy. (Linked to SLO 2.7)
2. Describe directly observed therapy. (Linked to SLO 2.7)
3. Describe hepatotoxicity monitoring during antituberculous therapy. (Linked to SLO 2.7)
4. Describe contact tracing. (Linked to SLO 2.8)
5. Describe Bacillus Calmette-Guérin vaccination. (Linked to SLO 2.8)

Series Summary

This Series covered tuberculosis across its full clinical spectrum. Part 2.1 covered the microbiology, transmission, and latent infection of tuberculosis, while Part 2.2 turned to pulmonary tuberculosis. Part 2.3 covered extrapulmonary tuberculosis, and Part 2.4 closed with the management and prevention of tuberculosis.

You should now be able to describe and manage pulmonary and extrapulmonary tuberculosis across all four Parts of this Series, meeting the outcomes set for this Series. Series 3 turns next to viral respiratory tract infections and chronic obstructive lung disease.

Glossary of Terms

1. **Bacillus Calmette-Guérin vaccination:** a vaccine offering partial protection against severe tuberculosis.
2. **Directly observed therapy:** supervised medication administration ensuring reliable treatment adherence.
3. **Extensively drug-resistant tuberculosis:** resistance extending to key second-line antituberculous agents.
4. **Ghon complex:** the primary infection focus and associated lymph node involvement in tuberculosis.
5. **Latent tuberculosis infection:** a dormant, asymptomatic, non-infectious state following primary infection.
6. **Miliary tuberculosis:** widespread haematogenous dissemination producing numerous small lesions.



7. **Multidrug-resistant tuberculosis:** resistance to at least the two most important first-line agents.
8. **Mycobacterium tuberculosis:** the organism causing tuberculosis, with a distinctive lipid-rich cell wall.
9. **Pott's disease:** spinal tuberculosis, presenting with back pain and potential deformity.
10. **Reactivation:** active disease developing from previously dormant latent infection.
11. **Sterile pyuria:** urinary white cells without a positive standard bacterial culture.
12. **Tuberculous lymphadenitis:** scrofula, painless, progressive lymph node enlargement from tuberculosis.

Concept Check Questions [Series 2]

Objective questions

- The lipid-rich cell wall of Mycobacterium tuberculosis directly confers its characteristic acid-fast _____ property. (Linked to SLO 2.1)
- Reactivation of latent tuberculosis infection occurs if host immune defence subsequently becomes genuinely _____. (Linked to SLO 2.2)
- Molecular diagnostic techniques can simultaneously detect resistance to key first-line antituberculous _____. (Linked to SLO 2.4)
- Tuberculous lymphadenitis is commonly termed scrofula when affecting the _____ lymph nodes. (Linked to SLO 2.5)
- Bacillus Calmette-Guérin vaccination is particularly genuinely valuable against severe _____ disease in young children. (Linked to SLO 2.8)

Short-answer questions

1. Describe the Ghon complex. (Linked to SLO 2.1)
2. Describe the classic clinical presentation of pulmonary tuberculosis. (Linked to SLO 2.3)
3. Distinguish multidrug-resistant from extensively drug-resistant tuberculosis. (Linked to SLO 2.4)
4. Describe Pott's disease. (Linked to SLO 2.6)
5. Describe directly observed therapy. (Linked to SLO 2.7)

Long-answer questions

6. Discuss the microbiology, transmission, and latent infection and reactivation of tuberculosis. (Linked to SLO 2.1, 2.2)
7. Describe the presentation, investigation, diagnosis, and drug resistance of pulmonary tuberculosis. (Linked to SLO 2.3, 2.4)



8. Discuss extrapulmonary tuberculosis, including lymphadenitis, pleural, meningeal, skeletal, and genitourinary disease. (Linked to SLO 2.5, 2.6)
9. Describe the principles, monitoring, and complications of antituberculous therapy. (Linked to SLO 2.7)
10. Discuss the prevention and public health control of tuberculosis. (Linked to SLO 2.8)

Answers to Concept Check Questions [Series 2]

Objective questions

11. Staining.
12. Compromised.
13. Drugs.
14. Cervical.
15. Disseminated.

Short-answer questions

16. The Ghon complex is the primary infection focus and associated lymph node involvement.
17. Presentation includes chronic cough, haemoptysis, weight loss, night sweats, and fever.
18. Multidrug-resistant disease resists key first-line agents; extensively drug-resistant disease extends to second-line agents.
19. Pott's disease is spinal tuberculosis presenting with back pain and potential deformity.
20. Directly observed therapy is supervised medication administration ensuring reliable adherence.

Long-answer questions

21. **Basic response:** Mycobacterium tuberculosis has a distinctive lipid-rich cell wall, transmitted through airborne droplets; primary infection is usually contained, producing latent infection capable of reactivation if immunity is compromised.

Value-added response: A value-added response notes that the Ghon complex reflects the primary infection focus and associated lymph node involvement.

22. **Basic response:** Pulmonary tuberculosis presents chronically with cough, haemoptysis, and weight loss; investigation uses chest radiography, sputum microscopy, and culture; drug-resistant disease is classified as multidrug or extensively drug-resistant.



Value-added response: A value-added response notes that molecular tests can rapidly detect resistance to key first-line drugs.

23. **Basic response:** Extrapulmonary sites include lymph nodes, pleura, central nervous system, spine, and genitourinary tract, each with a characteristic presentation and diagnostic approach.

Value-added response: A value-added response notes that miliary tuberculosis represents widespread haematogenous dissemination, particularly in immunocompromised patients.

24. **Basic response:** Treatment combines multiple agents across an intensive then continuation phase; monitoring addresses hepatotoxicity, visual disturbance, and peripheral neuropathy.

Value-added response: A value-added response notes that directly observed therapy addresses adherence risk and reduces resistance emergence.

25. **Basic response:** Prevention combines contact tracing, latent infection treatment in higher-risk contacts, vaccination, and infection control measures.

Value-added response: A value-added response notes that BCG vaccination is particularly valuable against severe disseminated disease in young children.

Answers to Pilot Questions [Series 2]

Part 2.1

1. The cell wall is lipid-rich, conferring acid-fast staining and resistance to standard Gram stain.
2. Transmission occurs through inhalation of small, airborne droplet nuclei following close contact.
3. The Ghon complex is the primary infection focus and associated lymph node involvement.
4. Latent infection is a dormant, asymptomatic, non-infectious state with a viable, contained organism.
5. Triggers include ageing, immunosuppressive medication, and specific conditions including HIV infection.



Part 2.2

6. Presentation includes chronic cough, haemoptysis, weight loss, night sweats, and fever.
7. Findings include upper lobe infiltrate and, in advanced disease, cavitation.
8. Sputum microscopy detects acid-fast bacilli, providing rapid supportive evidence.
9. Multidrug-resistant disease resists key first-line agents; extensively drug-resistant disease extends resistance to second-line agents.
10. Inadequate treatment allows selection of resistant organism subpopulations to persist and proliferate.

Part 2.3

11. Tuberculous lymphadenitis presents with painless, progressive lymph node enlargement.
12. Pleural disease presents with effusion, pleuritic pain, and breathlessness from a hypersensitivity reaction.
13. Pott's disease is spinal tuberculosis presenting with back pain and potential deformity.
14. Genitourinary tuberculosis can present with sterile pyuria alongside specific genitourinary symptoms.
15. Miliary tuberculosis is widespread haematogenous dissemination producing numerous small lesions.

Part 2.4

1. Standard treatment uses four agents during an intensive phase, then a reduced continuation phase.
2. Directly observed therapy is supervised medication administration ensuring reliable adherence.
3. Hepatotoxicity requires regular liver function monitoring, particularly during initial treatment weeks.
4. Contact tracing systematically identifies and screens close contacts of a confirmed infectious case.
5. BCG vaccination offers partial protection, particularly against severe disseminated disease in young children.



References and Attributions [Series 2]

1. Kumar, P., & Clark, M. (2020). Kumar and Clark's Clinical Medicine (10th ed.). Elsevier.
2. World Health Organization (2023). Global Tuberculosis Report. WHO.
3. National Institute for Health and Care Excellence (2016). Tuberculosis (NG33). NICE.
4. Mandell, G. L., Bennett, J. E., & Dolin, R. (2019). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (9th ed.). Elsevier.

Figures, Plates, Tables, and Boxes

1. Figure 2.1: A labelled diagram of granuloma formation surrounding *Mycobacterium tuberculosis*. AI-generated using the prompt: "Create a clean, accurate labelled educational diagram titled Granuloma Formation in Tuberculosis, showing a cross-section of a granuloma with labelled central necrotic material surrounded by macrophages and lymphocytes. Educational anatomical diagram style, no photographic content."
2. Table 2.1: Comparing latent and active pulmonary tuberculosis. AI-generated using the prompt: "Create a clean reference table titled Comparing Latent and Active Pulmonary Tuberculosis, listing feature, latent infection, and active pulmonary disease. Simple clinical reference table style with outside border."
3. Figure 2.2: Enlarged cervical lymph nodes characteristic of tuberculous lymphadenitis. AI-generated using the prompt: "Create a realistic clinical illustration titled Cervical Lymphadenopathy in Tuberculous Lymphadenitis, showing a patient's neck with visible swelling and enlargement of lymph nodes along one side, clinical examination setting, respectful and clinical in tone. Clean clinical illustration style, no text."
4. Table 2.2: Comparing first-line antituberculous drugs and their genuinely notable side effects. AI-generated using the prompt: "Create a clean reference table titled Comparing First-Line Antituberculous Drugs and Side Effects, listing drug, genuinely notable side effect, and monitoring requirement. Simple clinical reference table style with outside border."



Course code: MED 618

Course title: Pulmonology II

Course credit load: 2 Units

Series 3: Viral Respiratory Tract Infections and Chronic Obstructive Lung Disease

- **Part 3.1: Viral Respiratory Tract Infections**
 - Sub Part 3.1.1: Common cold and upper respiratory viral infections
 - Sub Part 3.1.2: Viral pneumonia
 - Sub Part 3.1.3: Influenza and its pulmonary complications
- **Part 3.2: Chronic Bronchitis and Emphysema**
 - Sub Part 3.2.1: Pathophysiology and risk factors of chronic obstructive lung disease
 - Sub Part 3.2.2: Chronic bronchitis
 - Sub Part 3.2.3: Emphysema
- **Part 3.3: Clinical Assessment and Diagnosis of COPD**
 - Sub Part 3.3.1: Clinical presentation of COPD
 - Sub Part 3.3.2: Investigation and diagnosis of COPD
 - Sub Part 3.3.3: Staging and severity assessment of COPD
- **Part 3.4: Management of COPD**
 - Sub Part 3.4.1: General management principles of stable COPD
 - Sub Part 3.4.2: Pharmacological management of COPD
 - Sub Part 3.4.3: Acute exacerbations of COPD



Introduction

This Series turns first to **viral respiratory tract infections**, spanning the genuinely common, generally mild upper respiratory viral infections through to viral pneumonia and influenza, before moving to **chronic obstructive lung disease**, a genuinely major, progressive respiratory condition comprising chronic bronchitis and emphysema, covered here from underlying pathophysiology through to structured, staged management.

The aim of this Series is to equip you with an understanding of viral upper respiratory tract infections and viral pneumonia, influenza and its pulmonary complications, the pathophysiology, risk factors, chronic bronchitis, and emphysema of chronic obstructive lung disease, the clinical presentation, investigation, diagnosis, and staging of COPD, and the general and pharmacological management of stable COPD and acute exacerbations.

This Series opens with **viral respiratory tract infections**, moves through **chronic bronchitis and emphysema** and **clinical assessment and diagnosis of COPD**, and closes with **management of COPD**.

Series Learning Outcomes

At the end of this Series, you should be able to:

- **SLO 3.1:** describe viral upper respiratory tract infections and viral pneumonia
- **SLO 3.2:** discuss influenza and its pulmonary complications
- **SLO 3.3:** describe the pathophysiology and risk factors of chronic obstructive lung disease, including chronic bronchitis and emphysema
- **SLO 3.4:** discuss chronic bronchitis and emphysema as distinct clinical phenotypes
- **SLO 3.5:** describe the clinical presentation, investigation, and diagnosis of COPD
- **SLO 3.6:** discuss the staging and severity assessment of COPD
- **SLO 3.7:** describe the general and pharmacological management of stable COPD
- **SLO 3.8:** discuss acute exacerbations of COPD

3.1 Viral Respiratory Tract Infections

3.1.1 common cold and upper respiratory viral infections



Genuinely mild, self-limiting, and genuinely common

The **common cold**, most commonly caused by rhinovirus, already introduced in principle in an earlier course of this programme, produces mild upper respiratory symptoms, nasal congestion, sore throat, and mild cough, following a genuinely predictable, self-limiting course, and, given this genuinely benign natural history, management remains genuinely supportive, without requiring specific antiviral treatment or, genuinely importantly, antibiotic therapy given the viral, rather than bacterial, aetiology.

Other respiratory viruses, including parainfluenza virus and respiratory syncytial virus, already discussed in principle in an earlier course of this programme, can produce a genuinely similar, generally mild upper respiratory presentation in adults, though genuinely, these same viruses can produce considerably more significant lower respiratory tract disease in young children or older, more vulnerable adults, a genuinely important age-dependent severity pattern this Part aims to establish.

Fill in the blank: The common cold, most commonly caused by rhinovirus, follows a genuinely predictable, self-limiting _____.

3.1.2 viral pneumonia

A genuinely important cause of lower respiratory tract infection

Viral pneumonia, infection of the lung parenchyma by a respiratory virus rather than bacteria, presents with a clinical picture genuinely overlapping considerably with the bacterial pneumonia already discussed in the previous Series of this course, though genuinely, certain specific features, including a more diffuse pattern on chest imaging and a genuinely less dramatic elevation in inflammatory markers, can provide supportive, though genuinely not definitive, clues towards a viral rather than bacterial cause.

Secondary bacterial pneumonia, genuinely, commonly complicating an initial viral respiratory infection, particularly influenza discussed further in the following sub-Part, reflects genuine disruption of normal respiratory tract defence mechanisms by the initial viral infection, and actively considering this specific possibility in a patient with apparent viral respiratory infection who subsequently, genuinely deteriorates or fails to improve as expected genuinely matters clinically.

Fill in the blank: Secondary bacterial pneumonia commonly complicates viral respiratory infection through genuine disruption of normal respiratory tract _____ mechanisms.



3.1.3 influenza and its pulmonary complications

Building on the earlier general introduction with a genuinely specific pulmonary focus

Influenza, already introduced in genuine depth in an earlier course of this programme covering its general presentation, seasonal pattern, and antigenic variation, is revisited here with a genuinely specific pulmonary focus, since influenza itself can genuinely, directly produce viral pneumonia already discussed in the previous sub-Part, alongside the genuinely, commonly encountered secondary bacterial pneumonia complication also already discussed.

High-risk patients, already discussed in principle in that earlier general influenza coverage, carry genuinely elevated risk of these specific pulmonary complications, and prompt recognition of genuine clinical deterioration in a patient with suspected or confirmed influenza, rather than assuming a benign, self-limiting course throughout, genuinely matters given the potential severity these specific pulmonary complications can produce in this genuinely vulnerable patient population.

Fill in the blank: High-risk patients carry genuinely elevated risk of the specific pulmonary complications influenza can _____.

Assessing Suspected Viral Pneumonia



Figure 3.1: A clinician assessing a patient with suspected viral pneumonia.



Pilot questions 3.1

- Describe the common cold and its typical management. (Linked to SLO 3.1)
- Describe viral pneumonia and its clinical overlap with bacterial pneumonia. (Linked to SLO 3.1)
- Explain why secondary bacterial pneumonia commonly complicates viral respiratory infection. (Linked to SLO 3.1)
- Describe influenza's specific pulmonary complications. (Linked to SLO 3.2)
- Explain why prompt recognition of deterioration in influenza genuinely matters. (Linked to SLO 3.2)

3.2 Chronic Bronchitis and Emphysema

3.2.1 pathophysiology and risk factors of chronic obstructive lung disease

Progressive, largely irreversible airflow limitation

Chronic obstructive lung disease, encompassing chronic bronchitis and emphysema, results from chronic inflammation of the airways and lung parenchyma producing progressive, largely irreversible airflow limitation, and **smoking**, by a genuinely considerable margin the most significant risk factor, directly drives the underlying inflammatory process in the great majority of affected patients, though genuine occupational exposure and, less commonly, a specific genetic deficiency also contribute in certain patients.

This genuinely progressive, largely irreversible airflow limitation, in genuine contrast to the more reversible airflow limitation characteristic of asthma discussed in a later Series of this course, directly reflects the underlying structural airway and parenchymal damage this condition produces, and understanding this specific pathophysiological distinction directly explains the different management emphasis these two genuinely distinct obstructive lung conditions require.

Fill in the blank: Smoking, by a genuinely considerable margin, is the most significant risk factor for chronic obstructive lung _____.



3.2.2 chronic bronchitis

A clinically defined diagnosis, genuinely based on symptom duration

Chronic bronchitis, genuinely defined clinically as a productive cough occurring on most days for at least three months in each of two consecutive years, reflects chronic airway inflammation and excess mucus production, and this specific, genuinely time-based clinical definition, rather than a purely histological diagnosis, directly guides recognition of this specific chronic obstructive lung disease phenotype in routine clinical practice.

Patients with a predominantly chronic bronchitis phenotype have historically been described using the somewhat informal descriptive term reflecting their genuinely characteristic productive cough and, in more advanced disease, cyanosis and fluid retention from associated right-sided heart strain, though genuinely, most affected patients demonstrate a genuine, meaningful overlap between chronic bronchitis and the emphysema phenotype discussed in the following sub-Part rather than a purely isolated presentation.

Fill in the blank: Chronic bronchitis is genuinely defined clinically as a productive cough occurring on most days for at least three months in each of two consecutive _____.

3.2.3 emphysema

Genuine destruction of the alveolar walls, reducing gas-exchanging surface area

Emphysema, genuine destruction of the alveolar walls distal to the terminal bronchiole, directly reduces the lung's overall gas-exchanging surface area and produces genuine loss of the normal elastic recoil that would otherwise support airway patency during expiration, together directly contributing to the characteristic airflow limitation this Part's opening sub-Part has already established as the fundamental pathophysiological hallmark of chronic obstructive lung disease.

Patients with a predominantly emphysematous phenotype have historically been described using a somewhat informal descriptive term reflecting their genuinely characteristic breathlessness and pursed-lip breathing pattern, a genuinely adaptive technique helping maintain positive airway pressure during expiration, and, as already noted in the previous sub-Part, genuine overlap between the chronic bronchitis and emphysema phenotypes is genuinely, considerably more common than either presenting in a purely isolated form.

Fill in the blank: Emphysema produces genuine loss of the normal elastic recoil that would otherwise support airway patency during _____.



Table 3.1: Comparing chronic bronchitis and emphysema phenotypes

Feature	Chronic bronchitis phenotype	Emphysema phenotype
Predominant symptom	Productive cough	Breathlessness
Underlying pathology	Airway inflammation, mucus hypersecretion	Alveolar wall destruction
Genuine clinical overlap	Considerable overlap between phenotypes is genuinely common	Considerable overlap between phenotypes is genuinely common

Pilot questions 3.2

1. Describe the pathophysiology of chronic obstructive lung disease. (Linked to SLO 3.3)
2. List risk factors for chronic obstructive lung disease. (Linked to SLO 3.3)
3. Describe the clinical definition of chronic bronchitis. (Linked to SLO 3.4)
4. Describe emphysema and its effect on gas-exchanging surface area. (Linked to SLO 3.4)
5. Explain why genuine overlap between chronic bronchitis and emphysema is common. (Linked to SLO 3.4)

3.3 Clinical Assessment and Diagnosis of COPD

3.3.1 clinical presentation of copd

Progressive breathlessness developing gradually over years

COPD presents with progressive breathlessness, chronic cough, and sputum production developing gradually over years, typically in a patient with a genuinely significant smoking history already discussed as the dominant risk factor earlier in this Series, and this genuinely gradual, insidious symptom development, often initially attributed by the patient themselves to simply ageing or reduced fitness, frequently means genuine disease progression has already occurred considerably before symptomatic presentation and formal diagnosis.

Examination findings in more advanced disease include hyperinflated chest, reduced breath sounds, and, in the emphysematous phenotype already discussed, the pursed-lip breathing pattern also already introduced, and these specific examination findings, alongside the characteristic



history already discussed, support the clinical diagnosis before formal confirmatory investigation, discussed in the following sub-Part of this Part.

Fill in the blank: COPD symptom development is often initially attributed by the patient themselves to simply ageing or reduced _____.

3.3.2 investigation and diagnosis of copd

Spirometry as the genuinely essential confirmatory investigation

Spirometry, measuring lung function including forced expiratory volume in one second and forced vital capacity, is the genuinely essential investigation confirming the diagnosis of COPD, demonstrating a characteristic obstructive pattern with genuinely limited reversibility following bronchodilator administration, a specific finding directly distinguishing COPD from the considerably more reversible airflow limitation characteristic of asthma already flagged earlier in this Series.

Chest radiography, genuinely useful for excluding alternative diagnoses and identifying specific complications rather than confirming the COPD diagnosis itself, and, in selected cases, further imaging or specific blood testing screening for the genetic deficiency already mentioned earlier in this Series, complete the genuinely comprehensive investigation approach to confirming and further characterising suspected COPD.

Fill in the blank: Spirometry demonstrates a characteristic obstructive pattern with genuinely limited reversibility following bronchodilator _____.

3.3.3 staging and severity assessment of copd

Combining lung function, symptoms, and exacerbation history

Staging by spirometric severity, categorising the specific degree of airflow limitation already confirmed through spirometry into structured severity grades, provides one important dimension of COPD severity assessment, though genuinely, this specific measure alone correlates only imperfectly with the patient's actual symptomatic burden and functional impact, meaning spirometric staging alone provides a genuinely incomplete picture of overall disease severity.

Comprehensive severity assessment, combining spirometric staging with structured symptom assessment and, genuinely importantly, the patient's exacerbation history, discussed further in the following Part of this Series, together provide a genuinely more complete, clinically meaningful picture of overall COPD severity, directly guiding the specific, individualised management approach discussed further in the following Part.



Fill in the blank: Comprehensive severity assessment combines spirometric staging with symptom assessment and exacerbation _____.

Spirometry Testing



Figure 3.2: A patient performing spirometry testing under clinical supervision.

Pilot questions 3.3

1. Describe the typical clinical presentation of COPD. (Linked to SLO 3.5)
2. Describe spirometry and its role in confirming COPD. (Linked to SLO 3.5)
3. Explain why the obstructive pattern in COPD shows limited reversibility. (Linked to SLO 3.5)
4. Describe spirometric severity staging in COPD. (Linked to SLO 3.6)
5. Explain why comprehensive severity assessment genuinely matters beyond spirometry alone. (Linked to SLO 3.6)

3.4 Management of COPD

3.4.1 general management principles of stable copd



Smoking cessation as the single most genuinely impactful intervention

Smoking cessation, given smoking's genuinely dominant role as the primary risk factor already established earlier in this Series, represents genuinely the single most impactful intervention available for slowing COPD disease progression, and active, structured support for smoking cessation forms a genuinely essential, foundational component of comprehensive COPD management applicable to essentially every affected patient who continues to smoke.

Pulmonary rehabilitation, a structured, multidisciplinary programme combining exercise training and education, genuinely, meaningfully improves symptoms, exercise capacity, and quality of life for appropriately selected patients, and **vaccination**, including influenza and pneumococcal vaccination already discussed in principle in earlier Series of this course, reduces the risk of the specific respiratory infections that can genuinely precipitate the exacerbations discussed in the following sub-Part.

Fill in the blank: Smoking cessation represents genuinely the single most impactful intervention available for slowing COPD disease _____.

3.4.2 pharmacological management of copd

A structured, stepwise approach matching treatment to symptom burden

Bronchodilator therapy, including short-acting and long-acting agents, forms the genuinely foundational pharmacological treatment for symptomatic COPD, relieving symptoms through relaxation of airway smooth muscle, and **inhaled corticosteroid therapy**, added for patients with more significant disease or a genuinely significant exacerbation history already discussed earlier in this Series, offers further symptomatic and exacerbation-reducing benefit in appropriately selected patients.

Treatment escalation, genuinely structured according to the comprehensive severity assessment already established in the previous Part, matches pharmacological treatment intensity to the individual patient's specific symptom burden and exacerbation risk, and this genuinely individualised, structured approach reflects the same treatment-matching philosophy already emphasised consistently throughout this whole course.

Fill in the blank: Bronchodilator therapy relieves symptoms through relaxation of airway smooth _____.



3.4.3 acute exacerbations of copd

Acute worsening requiring prompt, structured treatment escalation

Acute exacerbation of COPD, genuine acute worsening of symptoms beyond normal day-to-day variation, most commonly triggered by respiratory tract infection, viral or bacterial, already discussed extensively across this Series and the previous Series of this course, requires prompt recognition and treatment escalation, including increased bronchodilator therapy, a short course of oral corticosteroids, and, where genuine bacterial infection is suspected, antibiotic therapy.

Severity assessment during an exacerbation, evaluating the degree of respiratory compromise and any genuine indication for hospital admission, oxygen therapy, or, in severe cases, ventilatory support, discussed further in a later Series of this course covering respiratory failure, closes this Series's coverage on the theme of structured, severity-matched treatment escalation that has run consistently throughout this whole programme of respiratory medicine.

Fill in the blank: Acute exacerbation of COPD is genuine acute worsening of symptoms beyond normal day-to-day _____.

Table 3.2: Comparing stepwise pharmacological management options for stable COPD

Treatment class	Genuine mechanism	Typical treatment position
Short-acting bronchodilator	Relieves acute symptoms via smooth muscle relaxation	As-needed symptomatic relief
Long-acting bronchodilator	Sustained airway smooth muscle relaxation	Regular maintenance treatment
Inhaled corticosteroid	Reduces airway inflammation	Added for significant or exacerbation-prone disease

Pilot questions 3.4

1. Describe smoking cessation and its genuine importance in COPD management. (Linked to SLO 3.7)
2. Describe pulmonary rehabilitation. (Linked to SLO 3.7)
3. Describe the role of bronchodilator therapy. (Linked to SLO 3.7)
4. Describe acute exacerbation of COPD and its typical triggers. (Linked to SLO 3.8)
5. Describe the general treatment approach for an acute COPD exacerbation. (Linked to SLO 3.8)



Series Summary

This Series covered viral respiratory tract infections and chronic obstructive lung disease. Part 3.1 covered the common cold, viral pneumonia, and influenza's pulmonary complications, while Part 3.2 turned to the pathophysiology of chronic obstructive lung disease, chronic bronchitis, and emphysema. Part 3.3 covered the clinical assessment and diagnosis of COPD, and Part 3.4 closed with COPD management.

You should now be able to describe and manage viral respiratory tract infections and chronic obstructive lung disease across all four Parts of this Series, meeting the outcomes set for this Series. Series 4 turns next to bronchial asthma and respiratory failure.

Glossary of Terms

1. **Acute exacerbation of COPD:** genuine acute worsening of symptoms beyond normal day-to-day variation.
2. **Bronchodilator:** medication relaxing airway smooth muscle to relieve COPD symptoms.
3. **Chronic bronchitis:** productive cough occurring on most days for three months in each of two consecutive years.
4. **Chronic obstructive lung disease:** progressive, largely irreversible airflow limitation from chronic airway and parenchymal inflammation.
5. **Common cold:** mild, self-limiting upper respiratory viral infection, most commonly from rhinovirus.
6. **Emphysema:** destruction of alveolar walls reducing gas-exchanging surface area.
7. **Pulmonary rehabilitation:** a structured, multidisciplinary exercise and education programme for COPD.
8. **Pursed-lip breathing:** an adaptive breathing technique maintaining positive airway pressure during expiration.
9. **Secondary bacterial pneumonia:** bacterial pneumonia complicating an initial viral respiratory infection.
10. **Smoking cessation:** the single most impactful intervention for slowing COPD progression.
11. **Spirometry:** the essential lung function investigation confirming the diagnosis of COPD.
12. **Viral pneumonia:** lung parenchymal infection caused by a respiratory virus rather than bacteria.



Concept Check Questions [Series 3]

Objective questions

- The common cold, most commonly caused by rhinovirus, follows a genuinely predictable, self-limiting _____. (Linked to SLO 3.1)
- Smoking, by a genuinely considerable margin, is the most significant risk factor for chronic obstructive lung _____. (Linked to SLO 3.3)
- Spirometry demonstrates a characteristic obstructive pattern with genuinely limited reversibility following bronchodilator _____. (Linked to SLO 3.5)
- Smoking cessation represents genuinely the single most impactful intervention available for slowing COPD disease _____. (Linked to SLO 3.7)
- Acute exacerbation of COPD is genuine acute worsening of symptoms beyond normal day-to-day _____. (Linked to SLO 3.8)

Short-answer questions

1. Explain why secondary bacterial pneumonia commonly complicates viral respiratory infection. (Linked to SLO 3.1)
2. Describe the clinical definition of chronic bronchitis. (Linked to SLO 3.4)
3. Describe emphysema and its effect on gas-exchanging surface area. (Linked to SLO 3.4)
4. Explain why comprehensive severity assessment genuinely matters beyond spirometry alone. (Linked to SLO 3.6)
5. Describe the general treatment approach for an acute COPD exacerbation. (Linked to SLO 3.8)

Long-answer questions

6. Discuss viral upper respiratory tract infections, viral pneumonia, and influenza and its pulmonary complications. (Linked to SLO 3.1, 3.2)
7. Describe the pathophysiology, risk factors, chronic bronchitis, and emphysema of chronic obstructive lung disease. (Linked to SLO 3.3, 3.4)
8. Discuss the clinical presentation, investigation, diagnosis, and staging of COPD. (Linked to SLO 3.5, 3.6)
9. Describe the general and pharmacological management of stable COPD. (Linked to SLO 3.7)
10. Discuss acute exacerbations of COPD. (Linked to SLO 3.8)



Answers to Concept Check Questions [Series 3]

Objective questions

11. Course.
12. Disease.
13. Administration.
14. Progression.
15. Variation.

Short-answer questions

16. Viral infection genuinely disrupts normal respiratory tract defence mechanisms, allowing secondary bacterial infection.
17. Chronic bronchitis is productive cough on most days for three months in each of two consecutive years.
18. Emphysema destroys alveolar walls, directly reducing the lung's overall gas-exchanging surface area.
19. Spirometry correlates only imperfectly with actual symptomatic burden and functional impact alone.
20. Treatment includes increased bronchodilator therapy, a short corticosteroid course, and antibiotics if bacterial infection is suspected.

Long-answer questions

21. **Basic response:** The common cold is mild and self-limiting; viral pneumonia overlaps clinically with bacterial pneumonia; influenza can produce viral pneumonia and predispose to secondary bacterial pneumonia, particularly in high-risk patients.

Value-added response: A value-added response notes that certain imaging and laboratory features can suggest, though not definitively confirm, a viral cause.

22. **Basic response:** COPD results from chronic airway and parenchymal inflammation, most commonly from smoking; chronic bronchitis is defined by productive cough duration; emphysema is alveolar wall destruction.

Value-added response: A value-added response notes that genuine overlap between the two phenotypes is considerably more common than either presenting in isolation.

23. **Basic response:** COPD presents with gradually progressive breathlessness and cough; spirometry confirms diagnosis through limited-reversibility airflow obstruction; staging combines spirometric severity with symptoms and exacerbation history.



Value-added response: A value-added response notes that symptoms are often initially attributed to ageing rather than genuine disease.

24. **Basic response:** General management centres on smoking cessation, pulmonary rehabilitation, and vaccination; pharmacological management uses stepwise bronchodilator and inhaled corticosteroid therapy matched to severity.

Value-added response: A value-added response notes that smoking cessation is genuinely the single most impactful intervention available.

25. **Basic response:** Exacerbations are acute symptom worsening, most commonly from respiratory infection, requiring treatment escalation including bronchodilators, corticosteroids, and antibiotics where indicated.

Value-added response: A value-added response notes that severity assessment guides decisions on hospital admission and oxygen or ventilatory support.

Answers to Pilot Questions [Series 3]

Part 3.1

1. The common cold produces mild upper respiratory symptoms, managed supportively without antivirals or antibiotics.
2. Viral pneumonia clinically overlaps considerably with bacterial pneumonia, though some imaging features may differ.
3. Viral infection disrupts normal respiratory tract defence mechanisms, allowing secondary bacterial infection.
4. Complications include viral pneumonia and secondary bacterial pneumonia.
5. Prompt recognition allows timely escalation given the potential severity in vulnerable patients.

Part 3.2

6. COPD results from chronic airway and parenchymal inflammation producing progressive airflow limitation.
7. Risk factors include smoking, occupational exposure, and a specific genetic deficiency.
8. Chronic bronchitis is productive cough on most days for three months across two consecutive years.
9. Emphysema destroys alveolar walls, reducing the lung's overall gas-exchanging surface area.



10. Most patients demonstrate meaningful overlap between the two phenotypes rather than a purely isolated presentation.

Part 3.3

11. COPD presents with progressive breathlessness, chronic cough, and sputum production over years.
12. Spirometry measures lung function, confirming a characteristic obstructive pattern.
13. The obstructive pattern reflects structural airway and parenchymal damage rather than reversible bronchospasm.
14. Staging categorises the degree of airflow limitation confirmed on spirometry into structured severity grades.
15. Spirometry alone correlates only imperfectly with actual symptomatic burden and functional impact.

Part 3.4

1. Smoking cessation is genuinely the single most impactful intervention for slowing disease progression.
2. Pulmonary rehabilitation is a structured, multidisciplinary exercise and education programme.
3. Bronchodilator therapy relieves symptoms through airway smooth muscle relaxation.
4. Exacerbations are acute symptom worsening most commonly triggered by respiratory tract infection.
5. Treatment includes increased bronchodilators, a short corticosteroid course, and antibiotics where indicated.

References and Attributions [Series 3]

1. Kumar, P., & Clark, M. (2020). Kumar and Clark's Clinical Medicine (10th ed.). Elsevier.
2. Global Initiative for Chronic Obstructive Lung Disease (2024). Global Strategy for the Diagnosis, Management, and Prevention of COPD. GOLD.
3. British Thoracic Society (2023). Guidelines for the Management of COPD. Thorax.
4. National Institute for Health and Care Excellence (2019). Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NG115). NICE.



Figures, Plates, Tables, and Boxes

1. Figure 3.1: A clinician assessing a patient with suspected viral pneumonia. AI-generated using the prompt: "Create a realistic clinical illustration titled Assessing Suspected Viral Pneumonia, showing a clinician listening to a seated patient's chest with a stethoscope while checking a pulse oximeter reading on their finger, clinical examination room setting. Clean clinical illustration style, no text."
2. Table 3.1: Comparing chronic bronchitis and emphysema phenotypes. AI-generated using the prompt: "Create a clean reference table titled Comparing Chronic Bronchitis and Emphysema Phenotypes, listing feature, chronic bronchitis phenotype, and emphysema phenotype. Simple clinical reference table style with outside border."
3. Figure 3.2: A patient performing spirometry testing under clinical supervision. AI-generated using the prompt: "Create a realistic clinical illustration titled Spirometry Testing, showing a seated patient breathing forcefully into a spirometer mouthpiece while a clinician observes and coaches, clinical testing room setting. Clean clinical illustration style, no text."
4. Table 3.2: Comparing stepwise pharmacological management options for stable COPD. AI-generated using the prompt: "Create a clean reference table titled Comparing Stepwise Pharmacological Management Options for Stable COPD, listing treatment class, genuine mechanism, and typical treatment position. Simple clinical reference table style with outside border."



Course code: MED 618

Course title: Pulmonology II

Course credit load: 2 Units

Series 4: Bronchial Asthma and Respiratory Failure

- **Part 4.1: Pathophysiology and Clinical Presentation of Asthma**
 - Sub Part 4.1.1: Pathophysiology and triggers of asthma
 - Sub Part 4.1.2: Clinical presentation of asthma
 - Sub Part 4.1.3: Investigation and diagnosis of asthma
- **Part 4.2: Management of Asthma**
 - Sub Part 4.2.1: General management principles of stable asthma
 - Sub Part 4.2.2: Pharmacological management of asthma
 - Sub Part 4.2.3: Acute severe asthma
- **Part 4.3: Principles of Respiratory Failure**
 - Sub Part 4.3.1: Classification and pathophysiology of respiratory failure
 - Sub Part 4.3.2: Causes of type 1 and type 2 respiratory failure
 - Sub Part 4.3.3: Clinical presentation and investigation of respiratory failure
- **Part 4.4: Management of Respiratory Failure**
 - Sub Part 4.4.1: Oxygen therapy and general management
 - Sub Part 4.4.2: Non-invasive and invasive ventilatory support
 - Sub Part 4.4.3: Complications and prognosis of respiratory failure

Introduction

This Series turns to **bronchial asthma**, a genuinely common, chronic inflammatory airway condition characterised by reversible airflow limitation, standing in genuine, deliberate contrast to the largely irreversible airflow limitation of COPD already discussed in the previous Series of this course, before closing with **respiratory failure**, the genuinely serious, sometimes life-



threatening endpoint that severe disease from any respiratory condition, including asthma and COPD alike, can ultimately produce.

The aim of this Series is to equip you with an understanding of the pathophysiology, triggers, presentation, investigation, and diagnosis of asthma, the general and pharmacological management of stable asthma and acute severe asthma, the classification, pathophysiology, causes, presentation, and investigation of respiratory failure, and oxygen therapy, ventilatory support, complications, and prognosis of respiratory failure.

This Series opens with the **pathophysiology and clinical presentation of asthma**, moves through **management of asthma** and the **principles of respiratory failure**, and closes with **management of respiratory failure**.

Series Learning Outcomes

At the end of this Series, you should be able to:

- **SLO 4.1:** describe the pathophysiology, triggers, and clinical presentation of asthma
- **SLO 4.2:** discuss the investigation and diagnosis of asthma
- **SLO 4.3:** describe the general and pharmacological management of stable asthma
- **SLO 4.4:** discuss acute severe asthma
- **SLO 4.5:** describe the classification, pathophysiology, and causes of respiratory failure
- **SLO 4.6:** discuss the clinical presentation and investigation of respiratory failure
- **SLO 4.7:** describe oxygen therapy and ventilatory support in respiratory failure
- **SLO 4.8:** discuss the complications and prognosis of respiratory failure

4.1 Pathophysiology and Clinical Presentation of Asthma

4.1.1 pathophysiology and triggers of asthma

Genuinely reversible airway inflammation and hyperresponsiveness

Asthma, chronic airway inflammation producing genuine bronchial hyperresponsiveness, results in episodic, genuinely reversible airflow limitation through a combination of airway smooth muscle constriction, mucosal oedema, and excess mucus production, a genuinely distinct pathophysiological pattern from the largely irreversible, structural airway and parenchymal damage already established as characteristic of COPD in the previous Series of this course.



Common triggers, including allergen exposure, respiratory infection already discussed extensively across this course, cold air, exercise, and certain medications, precipitate genuine, acute worsening of the underlying chronic airway inflammation, and identifying a specific patient's individual trigger pattern, discussed further in relation to management in the following Part of this Series, genuinely supports both symptom prevention and overall disease control.

Fill in the blank: Asthma produces episodic, genuinely reversible airflow limitation through airway smooth muscle constriction, mucosal oedema, and excess _____ production.

4.1.2 clinical presentation of asthma

A genuinely characteristic, episodic symptom pattern

Asthma presents with episodic wheeze, breathlessness, chest tightness, and cough, characteristically genuinely worse at night or early morning and precipitated by the specific triggers already discussed, a genuinely distinctive episodic, variable symptom pattern directly contrasting with the more gradually progressive, persistent symptom pattern already established as characteristic of COPD in the previous Series of this course.

Examination during a symptomatic episode reveals widespread expiratory wheeze on auscultation, reflecting the airway narrowing already discussed, though genuinely, examination between episodes can be entirely normal, underlining why the specific symptomatic history, including the genuinely characteristic episodic, variable pattern already discussed, carries such considerable diagnostic weight in this specific condition.

Fill in the blank: Asthma symptoms are characteristically genuinely worse at night or early _____.

4.1.3 investigation and diagnosis of asthma

Demonstrating genuine variability in airflow limitation

Spirometry, already introduced in relation to COPD in the previous Series of this course, demonstrating an obstructive pattern with genuinely significant reversibility following bronchodilator administration, directly distinguishes asthma from the largely irreversible obstruction characteristic of COPD, and **peak flow monitoring**, tracking genuine variability in airflow over time, provides further supportive evidence for the diagnosis, particularly where spirometry itself proves genuinely inconclusive.

Fractional exhaled nitric oxide testing and specific allergy testing, where genuinely indicated, provide further supportive diagnostic evidence in selected, particularly diagnostically uncertain



cases, and this genuinely structured investigation approach, combining the characteristic clinical history already discussed with objective evidence of variable airflow limitation, together confirm the diagnosis with genuine confidence.

Fill in the blank: Peak flow monitoring tracks genuine variability in airflow over _____.




Figure 4.1: A labelled diagram of airway inflammation in asthma.

Pilot questions 4.1

- Describe the pathophysiology of asthma. (Linked to SLO 4.1)
- List common triggers of asthma. (Linked to SLO 4.1)
- Describe the characteristic clinical presentation of asthma. (Linked to SLO 4.1)
- Distinguish the airflow limitation of asthma from that of COPD. (Linked to SLO 4.2)
- Describe the role of spirometry and peak flow monitoring in diagnosing asthma. (Linked to SLO 4.2)

4.2 Management of Asthma

4.2.1 general management principles of stable asthma



Trigger avoidance alongside structured self-management

Trigger avoidance, where genuinely identifiable and practically feasible, and a **personalised asthma action plan**, providing structured, individualised guidance on recognising and responding to worsening symptoms, together form genuinely essential, foundational components of comprehensive asthma management, empowering patients to actively participate in their own ongoing disease control.

Regular review, monitoring symptom control and treatment adherence, genuinely allows timely adjustment of the specific pharmacological management approach discussed in the following sub-Part, and this genuinely structured, ongoing management approach reflects the same comprehensive, individualised long-term care philosophy already emphasised for other chronic conditions throughout this course.

Fill in the blank: A personalised asthma action plan provides structured, individualised guidance on recognising and responding to worsening _____.

4.2.2 pharmacological management of asthma

A structured, stepwise approach matching treatment to control

Short-acting bronchodilator therapy, used as needed for genuine symptom relief, forms the initial, foundational treatment step, and **inhaled corticosteroid therapy**, added for patients with genuinely more frequent symptoms or evidence of inadequate control on bronchodilator therapy alone, directly targets the underlying chronic airway inflammation already established as the fundamental pathophysiological driver of asthma earlier in this Series.

Stepwise treatment escalation, adding further controller medication for patients with disease genuinely inadequately controlled on initial treatment, and, correspondingly, **stepping down** treatment where genuine, sustained good control has been achieved, together reflect a genuinely dynamic, responsive treatment approach directly matching pharmacological intensity to the individual patient's current, genuine level of disease control.

Fill in the blank: Stepping down treatment is appropriate where genuine, sustained good _____ has been achieved.

4.2.3 acute severe asthma

A genuine medical emergency demanding immediate recognition

Acute severe asthma, genuine, significant acute worsening of asthma symptoms, presents with severe breathlessness, an inability to complete full sentences, and, in the most severe cases, a



genuinely silent chest, reflecting airflow so severely limited that wheeze itself becomes inaudible, a genuinely alarming finding that should never be mistaken for clinical improvement given what it actually represents.

Management of acute severe asthma requires immediate, aggressive bronchodilator therapy, systemic corticosteroids, and oxygen therapy, discussed further in the following two Parts of this Series, with genuinely close, structured monitoring for deterioration, and any patient failing to respond adequately to this initial treatment approach requires urgent escalation given the genuine, life-threatening potential this specific presentation carries.

Fill in the blank: A genuinely silent chest reflects airflow so severely limited that wheeze itself becomes _____.

Table 4.1: Comparing key asthma medication classes

Medication class	Genuine mechanism	Typical treatment position
Short-acting bronchodilator	Rapid airway smooth muscle relaxation	As-needed symptom relief
Inhaled corticosteroid	Reduces underlying airway inflammation	Regular controller therapy
Systemic corticosteroid	Rapid, powerful anti-inflammatory effect	Acute severe asthma treatment

Pilot questions 4.2

1. Describe trigger avoidance and personalised asthma action plans. (Linked to SLO 4.3)
2. Describe the stepwise pharmacological approach to asthma management. (Linked to SLO 4.3)
3. Describe acute severe asthma and its presentation. (Linked to SLO 4.4)
4. Explain why a silent chest is a genuinely alarming, rather than reassuring, finding. (Linked to SLO 4.4)
5. Describe the initial management of acute severe asthma. (Linked to SLO 4.4)

4.3 Principles of Respiratory Failure

4.3.1 classification and pathophysiology of respiratory failure



Genuine failure of the lung's fundamental gas exchange function

Respiratory failure, genuine, significant impairment of the lung's fundamental gas exchange function, is classified as **type 1**, genuine hypoxaemia without significant hypercapnia, reflecting a genuine ventilation-perfusion mismatch or diffusion impairment, or **type 2**, genuine hypoxaemia with significant hypercapnia, reflecting genuine, inadequate alveolar ventilation, a specific classification framework directly guiding the differential diagnosis and specific management approach discussed further later in this Series.

This genuinely fundamental distinction between the two types, reflecting genuinely distinct underlying pathophysiological mechanisms, directly explains why the specific management approach, discussed further in the following Part of this Series, genuinely differs between these two categories, particularly regarding the specific approach to supplemental oxygen therapy and ventilatory support.

Fill in the blank: Type 1 respiratory failure is genuine hypoxaemia without significant _____.

4.3.2 causes of type 1 and type 2 respiratory failure

A genuinely wide differential, spanning several conditions already discussed

Type 1 respiratory failure, resulting from conditions genuinely impairing gas exchange at the alveolar level, including the pneumonia already discussed in an earlier Series of this course and acute pulmonary oedema already discussed in an earlier course of this programme, reflects genuine, localised lung pathology without significant overall ventilatory failure.

Type 2 respiratory failure, resulting from conditions genuinely impairing overall ventilation, including severe COPD already discussed in the previous Series of this course, severe acute asthma already discussed earlier in this Series, and, less commonly, conditions genuinely affecting the respiratory muscles or their neurological control, reflects genuine, more widespread ventilatory compromise rather than localised gas exchange impairment alone.

Fill in the blank: Type 2 respiratory failure results from conditions genuinely impairing overall _____.

4.3.3 clinical presentation and investigation of respiratory failure

Confirming the genuine diagnosis and specific type through blood gas analysis

Respiratory failure presents with breathlessness, and, genuinely importantly, specific features reflecting the underlying type, cyanosis and confusion from hypoxaemia in both types, and, in



type 2 specifically, additional features from hypercapnia, including headache, drowsiness, and, in severe cases, genuine reduced consciousness, reflecting the specific physiological effects of the retained carbon dioxide characteristic of this specific type.

Arterial blood gas analysis, directly measuring oxygen and carbon dioxide levels, confirms the diagnosis and, genuinely essentially, distinguishes type 1 from type 2 respiratory failure already established in the previous sub-Part, directly guiding the specific management approach discussed further in the following Part of this Series, making this specific investigation genuinely essential rather than optional in any patient with suspected respiratory failure.

Fill in the blank: Arterial blood gas analysis directly measures oxygen and carbon dioxide levels, distinguishing type 1 from type _____ respiratory failure.

Arterial Blood Gas Sampling



Figure 4.2: A clinician performing arterial blood gas sampling.

Pilot questions 4.3

1. Distinguish type 1 from type 2 respiratory failure. (Linked to SLO 4.5)
2. List causes of type 1 respiratory failure. (Linked to SLO 4.5)
3. List causes of type 2 respiratory failure. (Linked to SLO 4.5)
4. Describe the clinical features of hypoxaemia and hypercapnia. (Linked to SLO 4.6)
5. Explain why arterial blood gas analysis is genuinely essential in suspected respiratory failure. (Linked to SLO 4.6)



4.4 Management of Respiratory Failure

4.4.1 oxygen therapy and general management

A genuinely important, type-specific therapeutic consideration

Supplemental oxygen therapy, correcting the hypoxaemia common to both types of respiratory failure already established earlier in this Series, requires genuinely careful, structured titration, and, in type 2 respiratory failure specifically, particularly in patients with underlying severe COPD already discussed in the previous Series of this course, genuinely careful, controlled oxygen delivery is required given the specific risk of worsening hypercapnia with overly liberal, uncontrolled oxygen administration in this specific patient population.

Treating the underlying cause, whether infection, exacerbation of underlying chronic respiratory disease already discussed extensively across this course, or another identified precipitant, remains genuinely essential alongside supportive oxygen therapy, and this genuinely comprehensive approach, addressing both the immediate physiological derangement and its underlying trigger, reflects the same treatment philosophy already emphasised consistently throughout this whole course.

Fill in the blank: Careful, controlled oxygen delivery is required in type 2 respiratory failure given the specific risk of worsening _____.

4.4.2 non-invasive and invasive ventilatory support

Escalating support where oxygen therapy alone proves inadequate

Non-invasive ventilation, providing ventilatory support through a genuinely tightly fitting mask rather than an invasive airway, offers effective support for appropriately selected patients, particularly in type 2 respiratory failure genuinely refractory to conservative measures already discussed, avoiding the genuine risks associated with invasive mechanical ventilation while still providing genuinely meaningful ventilatory assistance.

Invasive mechanical ventilation, requiring endotracheal intubation, is reserved for patients with respiratory failure genuinely refractory to non-invasive measures or those with a specific contraindication to non-invasive ventilation, and this structured, escalating approach to ventilatory support, matching intervention intensity to genuine clinical need, reflects the same escalation philosophy already established for other critical conditions throughout this course.



Fill in the blank: Invasive mechanical ventilation requires _____ intubation.

4.4.3 complications and prognosis of respiratory failure

Genuine risks reflecting both the underlying disease and its treatment

Complications of respiratory failure include the genuine consequences of prolonged hypoxaemia on other organ systems, and, where mechanical ventilation is genuinely required, specific ventilator-associated complications including the ventilator-associated pneumonia already discussed in principle in an earlier Series of this course, and active, structured monitoring for these specific complications forms an essential, ongoing component of comprehensive respiratory failure management.

Prognosis genuinely varies considerably depending on the underlying cause and the patient's overall physiological reserve, and this Series, and the whole of this course's coverage of respiratory infection, obstructive lung disease, and respiratory failure, closes on the same theme of structured, severity-matched, individualised clinical management that has run consistently throughout this entire programme of pulmonary medicine.

Fill in the blank: Prognosis in respiratory failure genuinely varies considerably depending on the underlying cause and the patient's overall physiological _____.

Table 4.2: Comparing type 1 and type 2 respiratory failure

Feature	Type 1 respiratory failure	Type 2 respiratory failure
Carbon dioxide level	Normal or low	Elevated
Common causes	Pneumonia, pulmonary oedema	Severe COPD, severe asthma
Oxygen therapy consideration	Standard titration	Genuinely careful, controlled titration

Pilot questions 4.4

1. Describe supplemental oxygen therapy in respiratory failure and the specific caution in type 2 disease. (Linked to SLO 4.7)
2. Describe non-invasive ventilation. (Linked to SLO 4.7)
3. Describe when invasive mechanical ventilation is genuinely indicated. (Linked to SLO 4.7)
4. List complications of respiratory failure. (Linked to SLO 4.8)



5. Describe the factors genuinely influencing prognosis in respiratory failure. (Linked to SLO 4.8)

Series Summary

This Series covered bronchial asthma and respiratory failure. Part 4.1 covered the pathophysiology, presentation, investigation, and diagnosis of asthma, while Part 4.2 turned to its general and pharmacological management and acute severe asthma. Part 4.3 covered the classification, causes, presentation, and investigation of respiratory failure, and Part 4.4 closed with the management of respiratory failure.

You should now be able to describe and manage bronchial asthma and respiratory failure across all four Parts of this Series, meeting the outcomes set for this Series. Series 5 turns next to carcinoma of the lungs, cryptogenic fibrosing alveolitis, and the pneumoconioses.

Glossary of Terms

1. **Acute severe asthma:** genuine, significant acute worsening of asthma symptoms, a medical emergency.
2. **Arterial blood gas analysis:** an investigation directly measuring oxygen and carbon dioxide levels.
3. **Asthma:** chronic airway inflammation producing episodic, reversible airflow limitation.
4. **Fractional exhaled nitric oxide testing:** a supportive investigation for suspected asthma.
5. **Invasive mechanical ventilation:** ventilatory support requiring endotracheal intubation.
6. **Non-invasive ventilation:** ventilatory support delivered through a tightly fitting mask.
7. **Peak flow monitoring:** tracking genuine variability in airflow over time for asthma assessment.
8. **Personalised asthma action plan:** individualised guidance on recognising and responding to worsening symptoms.
9. **Respiratory failure:** significant impairment of the lung's fundamental gas exchange function.
10. **Silent chest:** an alarming finding of severely limited airflow with inaudible wheeze.
11. **Type 1 respiratory failure:** hypoxaemia without significant hypercapnia.
12. **Type 2 respiratory failure:** hypoxaemia with significant hypercapnia from inadequate alveolar ventilation.



Concept Check Questions [Series 4]

Objective questions

- Asthma produces episodic, genuinely reversible airflow limitation through airway smooth muscle constriction, mucosal oedema, and excess _____ production. (Linked to SLO 4.1)
- Stepping down treatment is appropriate where genuine, sustained good _____ has been achieved. (Linked to SLO 4.3)
- Type 1 respiratory failure is genuine hypoxaemia without significant _____. (Linked to SLO 4.5)
- Careful, controlled oxygen delivery is required in type 2 respiratory failure given the specific risk of worsening _____. (Linked to SLO 4.7)
- Prognosis in respiratory failure genuinely varies considerably depending on the underlying cause and the patient's overall physiological _____. (Linked to SLO 4.8)

Short-answer questions

1. Distinguish the airflow limitation of asthma from that of COPD. (Linked to SLO 4.2)
2. Describe acute severe asthma and its presentation. (Linked to SLO 4.4)
3. Distinguish type 1 from type 2 respiratory failure. (Linked to SLO 4.5)
4. Describe non-invasive ventilation. (Linked to SLO 4.7)
5. List complications of respiratory failure. (Linked to SLO 4.8)

Long-answer questions

6. Discuss the pathophysiology, triggers, presentation, investigation, and diagnosis of asthma. (Linked to SLO 4.1, 4.2)
7. Describe the general and pharmacological management of stable asthma and acute severe asthma. (Linked to SLO 4.3, 4.4)
8. Discuss the classification, pathophysiology, causes, presentation, and investigation of respiratory failure. (Linked to SLO 4.5, 4.6)
9. Describe oxygen therapy and ventilatory support in respiratory failure. (Linked to SLO 4.7)
10. Discuss the complications and prognosis of respiratory failure. (Linked to SLO 4.8)



Answers to Concept Check Questions [Series 4]

Objective questions

11. Mucus.
12. Control.
13. Hypercapnia.
14. Hypercapnia.
15. Reserve.

Short-answer questions

16. Asthma airflow limitation is episodic and reversible, while COPD airflow limitation is progressive and largely irreversible.
17. Acute severe asthma presents with severe breathlessness, inability to complete sentences, and, in severe cases, a silent chest.
18. Type 1 is hypoxaemia without hypercapnia; type 2 is hypoxaemia with hypercapnia.
19. Non-invasive ventilation provides support through a tightly fitting mask rather than an invasive airway.
20. Complications include organ effects of prolonged hypoxaemia and ventilator-associated complications.

Long-answer questions

21. **Basic response:** Asthma is reversible airway inflammation triggered by allergens, infection, and other factors, presenting episodically with wheeze and breathlessness; diagnosis uses spirometry and peak flow monitoring demonstrating reversibility.

Value-added response: A value-added response notes that examination can be entirely normal between symptomatic episodes.

22. **Basic response:** General management includes trigger avoidance and action plans; pharmacological management uses stepwise bronchodilator and inhaled corticosteroid therapy; acute severe asthma requires immediate bronchodilators, corticosteroids, and oxygen.

Value-added response: A value-added response notes that a silent chest is a genuinely alarming sign of severely limited airflow, not clinical improvement.

23. **Basic response:** Respiratory failure is classified as type 1 or type 2 based on carbon dioxide level; causes include pneumonia and pulmonary oedema for type 1, and severe COPD or asthma for type 2; arterial blood gas analysis confirms diagnosis and type.



Value-added response: A value-added response notes that hypercapnia produces specific additional features including headache and drowsiness.

24. **Basic response:** Oxygen therapy requires careful titration, particularly controlled in type 2 disease; non-invasive ventilation offers support via mask, with invasive ventilation reserved for refractory cases.

Value-added response: A value-added response notes that this structured escalation approach matches intervention intensity to genuine clinical need.

25. **Basic response:** Complications include organ effects of prolonged hypoxaemia and ventilator-associated complications; prognosis varies with underlying cause and physiological reserve.

Value-added response: A value-added response notes that active, structured monitoring for complications forms an essential ongoing component of management.

Answers to Pilot Questions [Series 4]

Part 4.1

1. Asthma results from chronic airway inflammation producing bronchial hyperresponsiveness and reversible airflow limitation.
2. Triggers include allergen exposure, respiratory infection, cold air, exercise, and certain medications.
3. Presentation includes episodic wheeze, breathlessness, chest tightness, and cough, worse at night or early morning.
4. Asthma airflow limitation is episodic and reversible, while COPD is progressive and largely irreversible.
5. Spirometry demonstrates significant reversibility, and peak flow monitoring tracks variability over time.

Part 4.2

6. Trigger avoidance reduces symptom precipitants; action plans provide individualised self-management guidance.
7. Treatment starts with as-needed bronchodilators, adding inhaled corticosteroids and escalating as needed.



8. Acute severe asthma presents with severe breathlessness and inability to complete sentences.
9. A silent chest reflects airflow so limited that wheeze becomes inaudible, a sign of severe compromise.
10. Management requires immediate bronchodilators, systemic corticosteroids, and oxygen therapy.

Part 4.3

11. Type 1 is hypoxaemia without hypercapnia; type 2 is hypoxaemia with hypercapnia.
12. Causes of type 1 include pneumonia and acute pulmonary oedema.
13. Causes of type 2 include severe COPD, severe asthma, and respiratory muscle or neurological conditions.
14. Hypoxaemia causes cyanosis and confusion; hypercapnia additionally causes headache and drowsiness.
15. Arterial blood gas analysis confirms the diagnosis and distinguishes type 1 from type 2 disease.

Part 4.4

1. Oxygen therapy requires careful titration, with genuinely controlled delivery in type 2 disease given hypercapnia risk.
2. Non-invasive ventilation provides support through a tightly fitting mask rather than an invasive airway.
3. Invasive ventilation is indicated for disease refractory to non-invasive measures or with a specific contraindication.
4. Complications include organ effects of prolonged hypoxaemia and ventilator-associated complications.
5. Prognosis varies with the underlying cause and the patient's overall physiological reserve.

References and Attributions [Series 4]

1. Kumar, P., & Clark, M. (2020). Kumar and Clark's Clinical Medicine (10th ed.). Elsevier.
2. Global Initiative for Asthma (2024). Global Strategy for Asthma Management and Prevention. GINA.



3. British Thoracic Society (2019). SIGN/BTS British Guideline on the Management of Asthma. Thorax.
4. National Institute for Health and Care Excellence (2021). Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NG80). NICE.

Figures, Plates, Tables, and Boxes

1. Figure 4.1: A labelled diagram of airway inflammation in asthma. AI-generated using the prompt: "Create a clean, accurate labelled educational diagram titled Airway Changes in Asthma, showing a cross-section of a narrowed airway with labelled constricted smooth muscle, swollen mucosa, and excess mucus, compared with a normal airway cross-section. Educational anatomical diagram style, no photographic content."
2. Table 4.1: Comparing key asthma medication classes. AI-generated using the prompt: "Create a clean reference table titled Comparing Key Asthma Medication Classes, listing medication class, genuine mechanism, and typical treatment position. Simple clinical reference table style with outside border."
3. Figure 4.2: A clinician performing arterial blood gas sampling. AI-generated using the prompt: "Create a realistic clinical illustration titled Arterial Blood Gas Sampling, showing a clinician carefully inserting a needle into a patient's wrist to obtain an arterial blood sample, clinical procedure setting. Clean clinical illustration style, no text."
4. Table 4.2: Comparing type 1 and type 2 respiratory failure. AI-generated using the prompt: "Create a clean reference table titled Comparing Type 1 and Type 2 Respiratory Failure, listing feature, type 1 respiratory failure, and type 2 respiratory failure. Simple clinical reference table style with outside border."



Course code: MED 618

Course title: Pulmonology II

Course credit load: 2 Units

Series 5: Carcinoma of the Lungs, Cryptogenic Fibrosing Alveolitis, and the Pneumoconioses

- **Part 5.1: Carcinoma of the Lung I: Pathophysiology and Presentation**
 - Sub Part 5.1.1: Risk factors and classification of lung cancer
 - Sub Part 5.1.2: Clinical presentation of lung cancer
 - Sub Part 5.1.3: Paraneoplastic syndromes of lung cancer
- **Part 5.2: Carcinoma of the Lung II: Investigation and Management**
 - Sub Part 5.2.1: Investigation and staging of lung cancer
 - Sub Part 5.2.2: Management of non-small cell lung cancer
 - Sub Part 5.2.3: Management of small cell lung cancer
- **Part 5.3: Cryptogenic Fibrosing Alveolitis**
 - Sub Part 5.3.1: Pathophysiology of cryptogenic fibrosing alveolitis
 - Sub Part 5.3.2: Clinical presentation and diagnosis of cryptogenic fibrosing alveolitis
 - Sub Part 5.3.3: Management and prognosis of cryptogenic fibrosing alveolitis
- **Part 5.4: The Pneumoconioses**
 - Sub Part 5.4.1: Principles and classification of pneumoconiosis
 - Sub Part 5.4.2: Specific pneumoconioses
 - Sub Part 5.4.3: Prevention and management of pneumoconiosis



Introduction

This final Series closes the course with three genuinely important, distinct pulmonary conditions, **carcinoma of the lung**, a genuinely major cause of cancer mortality demanding structured recognition and management, **cryptogenic fibrosing alveolitis**, a genuinely progressive interstitial lung disease of unknown cause, and the **pneumoconioses**, occupational lung diseases resulting from genuine, specific inhaled dust exposure, each requiring the same structured, systematic clinical approach already emphasised throughout this course.

The aim of this Series is to equip you with an understanding of the risk factors, classification, presentation, paraneoplastic syndromes, investigation, staging, and management of lung cancer, the pathophysiology, presentation, diagnosis, management, and prognosis of cryptogenic fibrosing alveolitis, and the principles, classification, specific types, prevention, and management of the pneumoconioses.

This Series opens with **carcinoma of the lung I: pathophysiology and presentation**, moves through **carcinoma of the lung II: investigation and management** and **cryptogenic fibrosing alveolitis**, and closes with **the pneumoconioses**.

Series Learning Outcomes

At the end of this Series, you should be able to:

- **SLO 5.1:** describe the risk factors, classification, and clinical presentation of lung cancer
- **SLO 5.2:** describe paraneoplastic syndromes of lung cancer
- **SLO 5.3:** discuss the investigation and staging of lung cancer
- **SLO 5.4:** discuss the management of non-small cell and small cell lung cancer
- **SLO 5.5:** describe the pathophysiology, presentation, and diagnosis of cryptogenic fibrosing alveolitis
- **SLO 5.6:** discuss the management and prognosis of cryptogenic fibrosing alveolitis
- **SLO 5.7:** describe the principles, classification, and specific types of pneumoconiosis
- **SLO 5.8:** discuss the prevention and management of pneumoconiosis

5.1 Carcinoma of the Lung I: Pathophysiology and Presentation

5.1.1 risk factors and classification of lung cancer



Smoking as the genuinely dominant, though not exclusive, risk factor

Smoking, already established as the dominant risk factor for chronic obstructive lung disease in an earlier Series of this course, similarly represents the genuinely dominant risk factor for lung cancer, accounting for the great majority of cases, alongside occupational exposure, discussed further in relation to the pneumoconioses later in this Series, and, less commonly, genetic predisposition in patients without a significant smoking history.

Lung cancer is genuinely classified into **non-small cell lung cancer**, comprising the great majority of cases and further subdivided into several specific histological subtypes, and **small cell lung cancer**, a genuinely, considerably more aggressive subtype with a distinct biological behaviour and, correspondingly, a genuinely different management approach discussed further later in this Series, a classification carrying genuinely fundamental prognostic and treatment implications.

Fill in the blank: Lung cancer is genuinely classified into non-small cell lung cancer and small cell lung _____.

5.1.2 clinical presentation of lung cancer

A genuinely wide-ranging presentation, often, unfortunately, at a late stage

Lung cancer presents with persistent cough, haemoptysis, and weight loss, alongside breathlessness where genuine tumour bulk or associated complications affect normal lung function, and this genuinely non-specific early symptom pattern, frequently overlapping with the far more common, generally benign respiratory conditions already discussed extensively earlier in this course, unfortunately, frequently contributes to delayed diagnosis at a genuinely more advanced disease stage.

Local complications, including recurrent laryngeal nerve palsy producing hoarse voice, and superior vena cava obstruction, producing facial swelling and distended neck veins from tumour compression of this specific vessel, alongside **metastatic disease** presenting with symptoms reflecting the specific affected distant organ, complete the genuinely wide-ranging presentation this Part aims to establish confident recognition of.

Fill in the blank: Superior vena cava obstruction produces facial swelling and distended neck veins from tumour compression of this specific _____.

5.1.3 paraneoplastic syndromes of lung cancer



Systemic effects genuinely distant from the tumour itself

Paraneoplastic syndromes, systemic effects genuinely resulting from tumour-secreted substances rather than direct tumour invasion or metastasis, occur in a genuinely meaningful proportion of lung cancer patients, particularly small cell lung cancer given its genuinely distinctive neuroendocrine biological origin, and include **hypercalcaemia**, already discussed in principle in relation to myelomatosis in an earlier course of this programme, and **hyponatraemia** from inappropriate antidiuretic hormone secretion.

Finger clubbing, a genuinely characteristic, though not entirely specific, physical finding sometimes associated with lung cancer, and, in small cell lung cancer specifically, genuinely rare but recognised neurological paraneoplastic syndromes, together illustrate the genuinely wide-ranging systemic effects lung cancer can produce, and recognising these specific paraneoplastic patterns can occasionally provide the genuinely first clinical clue towards an underlying, previously unsuspected malignancy.

Fill in the blank: Paraneoplastic syndromes result from tumour-secreted substances rather than direct tumour invasion or _____.

Examining for Finger Clubbing



Figure 5.1: A clinician examining a patient's fingers for clubbing.



Pilot questions 5.1

- List risk factors for lung cancer. (Linked to SLO 5.1)
- Distinguish non-small cell from small cell lung cancer. (Linked to SLO 5.1)
- Describe the typical presenting symptoms of lung cancer. (Linked to SLO 5.1)
- Describe superior vena cava obstruction. (Linked to SLO 5.1)
- Describe paraneoplastic syndromes and give examples. (Linked to SLO 5.2)

5.2 Carcinoma of the Lung II: Investigation and Management

5.2.1 investigation and staging of lung cancer

Confirming the diagnosis and mapping its genuine extent

Chest imaging, typically identifying a suspicious lesion prompting further investigation, alongside **tissue biopsy**, obtained through bronchoscopy or other image-guided sampling techniques, confirms the histological diagnosis and specific subtype already discussed in the previous Part, and **staging investigations**, including cross-sectional and functional imaging, assess for both local extent and distant metastatic spread.

Accurate staging genuinely, directly determines treatment approach, since it distinguishes disease genuinely amenable to potentially curative treatment from disease where treatment intent genuinely shifts towards palliation, mirroring the same fundamental staging principle already established for other malignancies discussed elsewhere in this programme, and this genuinely essential staging step directly precedes the specific management discussion in the following two sub-Parts of this Part.

Fill in the blank: Accurate staging distinguishes disease genuinely amenable to potentially curative treatment from disease where treatment intent genuinely shifts towards _____.

5.2.2 management of non-small cell lung cancer

Surgical resection as the genuinely preferred curative approach

Surgical resection, removing the affected lung tissue, remains the genuinely preferred curative treatment approach for appropriately staged, localised non-small cell lung cancer in patients with adequate overall fitness to tolerate surgery, and **adjuvant chemotherapy**, given following



surgery for patients with higher-risk disease features, genuinely reduces recurrence risk in appropriately selected cases.

For patients with genuinely more advanced disease not amenable to surgical resection, **chemotherapy, radiotherapy**, and, increasingly, **targeted molecular therapy** directed against specific genetic mutations identified within the tumour, alongside immunotherapy, together offer genuinely meaningful treatment options, and this specific management approach is genuinely individualised according to the tumour's specific molecular characteristics and the patient's overall fitness and treatment goals.

Fill in the blank: Targeted molecular therapy is directed against specific genetic mutations identified within the _____.

5.2.3 management of small cell lung cancer

A genuinely different biological behaviour, a genuinely different treatment approach

Small cell lung cancer, given its genuinely, considerably more aggressive biological behaviour and frequent presentation with disease already genuinely too widespread for surgical resection by the time of diagnosis, is typically managed with **combination chemotherapy**, often alongside radiotherapy for disease genuinely confined to a treatable radiation field, in genuine contrast to the surgery-centred approach already established for earlier-stage non-small cell disease.

Prophylactic cranial irradiation, genuinely, specifically considered in appropriately selected patients given small cell lung cancer's genuinely elevated risk of brain metastasis, illustrates a further genuinely distinctive treatment consideration specific to this particular lung cancer subtype, and this genuinely different management approach, closing this Part's coverage, directly reflects the fundamentally distinct biological behaviour already established between these two major lung cancer categories.

Fill in the blank: Prophylactic cranial irradiation is considered given small cell lung cancer's genuinely elevated risk of brain _____.

Table 5.1: Comparing non-small cell and small cell lung cancer

Feature	Non-small cell lung cancer	Small cell lung cancer
Relative frequency	Most common overall	Less common
Typical biological behaviour	Generally less aggressive	Genuinely more aggressive
Primary treatment approach	Surgery for localised disease	Combination chemotherapy



Pilot questions 5.2

1. Describe the investigation and staging approach for suspected lung cancer. (Linked to SLO 5.3)
2. Explain why accurate staging genuinely matters clinically. (Linked to SLO 5.3)
3. Describe the management of localised non-small cell lung cancer. (Linked to SLO 5.4)
4. Describe targeted molecular therapy for advanced non-small cell lung cancer. (Linked to SLO 5.4)
5. Describe the general management approach for small cell lung cancer. (Linked to SLO 5.4)

5.3 Cryptogenic Fibrosing Alveolitis

5.3.1 pathophysiology of cryptogenic fibrosing alveolitis

Progressive, genuinely irreversible scarring of unknown cause

Cryptogenic fibrosing alveolitis, also termed idiopathic pulmonary fibrosis, is a genuinely progressive interstitial lung disease characterised by progressive, genuinely irreversible pulmonary fibrosis of genuinely unknown underlying cause, directly reflected in the term cryptogenic, and predominantly affects older adults, with the underlying pathophysiology involving genuinely abnormal, dysregulated tissue repair following repeated, subtle lung injury rather than a straightforward, ongoing inflammatory process alone.

This genuinely progressive fibrotic process directly reduces lung compliance and impairs normal gas exchange, and, unlike the largely reversible inflammatory process already established as characteristic of asthma in the previous Series of this course, the fibrotic tissue changes characteristic of this specific condition are genuinely, essentially irreversible once established, directly underlying the generally unfavourable natural history discussed further in the closing sub-Part of this Part.

Fill in the blank: Cryptogenic fibrosing alveolitis is a progressive interstitial lung disease of genuinely unknown underlying _____.

5.3.2 clinical presentation and diagnosis of cryptogenic fibrosing alveolitis



A genuinely gradual, insidious onset with characteristic examination findings

Progressive breathlessness on exertion and a **dry, non-productive cough**, developing gradually over months to years, represent the genuinely characteristic presenting symptoms, and examination reveals characteristic fine, bilateral, basal, inspiratory crackles, sometimes genuinely described as sounding like Velcro being pulled apart, alongside finger clubbing already introduced in relation to lung cancer earlier in this Series, in a genuinely meaningful proportion of affected patients.

High-resolution computed tomography, demonstrating a characteristic pattern of pulmonary fibrosis, forms the genuinely key diagnostic investigation, and, where the diagnosis remains genuinely uncertain following imaging alone, lung biopsy can provide additional supportive histological confirmation, though genuinely, this specific invasive investigation carries genuine risk in patients with significantly, already compromised lung function.

Fill in the blank: Examination reveals characteristic fine, bilateral, basal, inspiratory crackles, sometimes genuinely described as sounding like _____ being pulled apart.

5.3.3 management and prognosis of cryptogenic fibrosing alveolitis

Genuinely limited disease-modifying options, and a generally unfavourable prognosis

Antifibrotic medication, genuinely, specific agents slowing, though not reversing, the rate of disease progression, offers the most genuinely meaningful disease-modifying treatment option currently available for this specific condition, alongside comprehensive supportive care including supplemental oxygen therapy where genuinely indicated and pulmonary rehabilitation, already introduced in relation to COPD in an earlier Series of this course.

Lung transplantation, already discussed in principle for renal transplantation in an earlier course of this programme though applied here to a genuinely distinct organ, offers a genuinely curative option for appropriately selected, younger patients with severe disease, and, given the genuinely, generally unfavourable natural history this condition follows despite currently available treatment, prognosis genuinely remains guarded for the great majority of affected patients, closing this Part's coverage on a note of genuine clinical realism.

Fill in the blank: Antifibrotic medication slows, though does not reverse, the rate of disease _____.



Auscultating for Basal Crackles



Figure 5.2: A clinician auscultating a patient's lower back for fine, bilateral, basal crackles.

Pilot questions 5.3

1. Describe the pathophysiology of cryptogenic fibrosing alveolitis. (Linked to SLO 5.5)
2. Describe the typical presenting symptoms of cryptogenic fibrosing alveolitis. (Linked to SLO 5.5)
3. Describe the characteristic auscultation finding in cryptogenic fibrosing alveolitis. (Linked to SLO 5.5)
4. Describe the role of high-resolution computed tomography in diagnosis. (Linked to SLO 5.5)
5. Describe the management options and prognosis for cryptogenic fibrosing alveolitis. (Linked to SLO 5.6)



5.4 The Pneumoconioses

5.4.1 principles and classification of pneumoconiosis

Lung disease from genuine, specific occupational dust exposure

Pneumoconiosis, a genuine group of occupational lung diseases resulting from inhalation of specific mineral dust, produces lung damage through genuine, direct tissue toxicity or the chronic inflammatory response this inhaled material triggers, and this specific, occupational causation directly requires a genuinely thorough, structured occupational history when investigating suspected interstitial lung disease, complementing the cryptogenic fibrosing alveolitis already discussed in the previous Part where no such specific cause is identified.

Classification by the specific inhaled substance responsible directly determines both the specific radiological pattern and the genuine clinical behaviour a given pneumoconiosis demonstrates, and this genuinely occupation-linked classification framework directly underlies the specific types discussed in the following sub-Part of this Part, each requiring genuinely specific recognition of its particular characteristic occupational exposure pattern.

Fill in the blank: Pneumoconiosis produces lung damage through genuine, direct tissue toxicity or the chronic inflammatory _____ this inhaled material triggers.

5.4.2 specific pneumoconioses

Genuinely distinct occupational exposures, genuinely distinct clinical patterns

Coal worker's pneumoconiosis, resulting from coal dust inhalation, and **silicosis**, resulting from crystalline silica dust inhalation in occupations including mining and stone cutting, represent two of the genuinely most commonly encountered pneumoconioses, each producing a characteristic radiological nodular pattern, and silicosis specifically carries genuinely elevated additional risk of tuberculosis, already discussed extensively in an earlier Series of this course.

Asbestosis, resulting from asbestos fibre inhalation, carries genuinely, particularly significant additional malignancy risk, including both the lung cancer already discussed earlier in this Series and mesothelioma, a genuinely distinct, aggressive malignancy specifically, characteristically associated with asbestos exposure, illustrating how genuinely, considerably the specific inhaled substance shapes not just the immediate pulmonary fibrotic process but the patient's genuine, longer-term malignancy risk profile.

Fill in the blank: Asbestosis carries genuinely, particularly significant additional malignancy risk, including lung cancer and _____.



5.4.3 prevention and management of pneumoconiosis

Prevention genuinely, considerably preferable to treatment of established disease

Occupational exposure prevention, including workplace dust control measures and appropriate respiratory protective equipment, genuinely represents the most effective strategy for pneumoconiosis given the genuinely, essentially irreversible nature of established fibrotic lung damage once it has occurred, mirroring the same preventive philosophy already emphasised across this whole course wherever a condition's underlying cause proves genuinely, directly modifiable.

Management of established pneumoconiosis is genuinely largely supportive, mirroring the supportive care already established for cryptogenic fibrosing alveolitis earlier in this Series, given the genuinely limited disease-modifying treatment options available once established fibrotic damage has occurred, and this Series, and the entire course, closes on the theme of prevention alongside treatment, and structured, individualised clinical management, that has run consistently throughout this whole programme of pulmonary medicine.

Fill in the blank: Management of established pneumoconiosis is genuinely largely _____, mirroring the care already established for cryptogenic fibrosing alveolitis.

Table 5.2: Comparing common specific pneumoconioses

Pneumoconiosis	Causative dust exposure	Genuinely notable additional risk
Coal worker's pneumoconiosis	Coal dust	Progressive massive fibrosis in advanced disease
Silicosis	Crystalline silica dust	Elevated tuberculosis risk
Asbestosis	Asbestos fibres	Elevated lung cancer and mesothelioma risk

Pilot questions 5.4

1. Describe pneumoconiosis and why a thorough occupational history genuinely matters. (Linked to SLO 5.7)
2. Describe coal worker's pneumoconiosis. (Linked to SLO 5.7)
3. Describe silicosis and its additional risk. (Linked to SLO 5.7)
4. Describe asbestosis and its additional malignancy risk. (Linked to SLO 5.7)



5. Describe the prevention and general management approach for pneumoconiosis. (Linked to SLO 5.8)

Series Summary

This final Series closed the course with carcinoma of the lung, cryptogenic fibrosing alveolitis, and the pneumoconioses. Part 5.1 covered the risk factors, presentation, and paraneoplastic syndromes of lung cancer, while Part 5.2 turned to its investigation, staging, and management. Part 5.3 covered cryptogenic fibrosing alveolitis, and Part 5.4 closed with the pneumoconioses.

You should now be able to describe and manage lung cancer, cryptogenic fibrosing alveolitis, and the pneumoconioses across all four Parts of this Series, meeting the outcomes set for this Series. Across the full course, Series 1 covered respiratory tract infections and bacterial pneumonias, Series 2 covered tuberculosis, pulmonary and extrapulmonary disease, Series 3 covered viral respiratory tract infections and chronic obstructive lung disease, Series 4 covered bronchial asthma and respiratory failure, and this Series has closed the course with carcinoma of the lungs, cryptogenic fibrosing alveolitis, and the pneumoconioses, together forming a comprehensive foundation in Pulmonology II.

Glossary of Terms

1. **Asbestosis:** pulmonary fibrosis from asbestos fibre inhalation, carrying malignancy risk.
2. **Coal worker's pneumoconiosis:** occupational lung disease from coal dust inhalation.
3. **Cryptogenic fibrosing alveolitis:** idiopathic pulmonary fibrosis of genuinely unknown underlying cause.
4. **High-resolution computed tomography:** the key diagnostic imaging investigation for interstitial lung disease.
5. **Mesothelioma:** an aggressive malignancy characteristically associated with asbestos exposure.
6. **Non-small cell lung cancer:** the most common lung cancer category, generally less aggressive.
7. **Paraneoplastic syndrome:** a systemic effect from tumour-secreted substances rather than direct invasion.
8. **Pneumoconiosis:** occupational lung disease resulting from inhalation of specific mineral dust.



9. **Prophylactic cranial irradiation:** preventive radiotherapy given the elevated brain metastasis risk in small cell lung cancer.
10. **Silicosis:** occupational lung disease from crystalline silica dust, with elevated tuberculosis risk.
11. **Small cell lung cancer:** a considerably more aggressive lung cancer subtype of neuroendocrine origin.
12. **Superior vena cava obstruction:** tumour compression of the superior vena cava causing facial swelling.

Concept Check Questions [Series 5]

Objective questions

- Lung cancer is genuinely classified into non-small cell lung cancer and small cell lung _____. (Linked to SLO 5.1)
- Paraneoplastic syndromes result from tumour-secreted substances rather than direct tumour invasion or _____. (Linked to SLO 5.2)
- Accurate staging distinguishes disease genuinely amenable to potentially curative treatment from disease where treatment intent genuinely shifts towards _____. (Linked to SLO 5.3)
- Cryptogenic fibrosing alveolitis is a progressive interstitial lung disease of genuinely unknown underlying _____. (Linked to SLO 5.5)
- Asbestosis carries genuinely, particularly significant additional malignancy risk, including lung cancer and _____. (Linked to SLO 5.7)

Short-answer questions

1. Distinguish non-small cell from small cell lung cancer. (Linked to SLO 5.1)
2. Describe the management of localised non-small cell lung cancer. (Linked to SLO 5.4)
3. Describe the characteristic auscultation finding in cryptogenic fibrosing alveolitis. (Linked to SLO 5.5)
4. Describe silicosis and its additional risk. (Linked to SLO 5.7)
5. Describe the prevention and general management approach for pneumoconiosis. (Linked to SLO 5.8)

Long-answer questions

6. Discuss the risk factors, classification, presentation, and paraneoplastic syndromes of lung cancer. (Linked to SLO 5.1, 5.2)



7. Describe the investigation, staging, and management of non-small cell and small cell lung cancer. (Linked to SLO 5.3, 5.4)
8. Discuss the pathophysiology, presentation, diagnosis, management, and prognosis of cryptogenic fibrosing alveolitis. (Linked to SLO 5.5, 5.6)
9. Describe the principles, classification, and specific types of pneumoconiosis. (Linked to SLO 5.7)
10. Discuss the prevention and management of pneumoconiosis. (Linked to SLO 5.8)

Answers to Concept Check Questions [Series 5]

Objective questions

11. Cancer.
12. Metastasis.
13. Palliation.
14. Cause.
15. Mesothelioma.

Short-answer questions

16. Non-small cell lung cancer is more common and less aggressive; small cell is less common and more aggressive.
17. Localised non-small cell lung cancer is managed with surgical resection, with adjuvant chemotherapy for higher-risk disease.
18. Examination reveals fine, bilateral, basal, inspiratory crackles, sometimes described as sounding like Velcro.
19. Silicosis results from crystalline silica dust exposure, carrying elevated tuberculosis risk.
20. Prevention centres on occupational dust control and protective equipment; management of established disease is largely supportive.

Long-answer questions

21. **Basic response:** Smoking is the dominant risk factor; cancer is classified as non-small cell or small cell; presentation includes cough, haemoptysis, and weight loss; paraneoplastic syndromes include hypercalcaemia and hyponatraemia.

Value-added response: A value-added response notes that paraneoplastic patterns can occasionally provide the first clinical clue to an underlying malignancy.



22. **Basic response:** Investigation combines imaging and biopsy with staging investigations; non-small cell disease is managed with surgery for localised disease, chemotherapy and targeted therapy for advanced disease; small cell disease is managed with combination chemotherapy given its aggressive behaviour.

Value-added response: A value-added response notes that prophylactic cranial irradiation is considered given the elevated brain metastasis risk in small cell disease.

23. **Basic response:** Cryptogenic fibrosing alveolitis is progressive fibrosis of unknown cause, presenting with breathlessness and dry cough; diagnosis uses high-resolution CT; management uses antifibrotic medication and supportive care, with a generally guarded prognosis.

Value-added response: A value-added response notes that lung transplantation offers a curative option for appropriately selected, younger patients.

24. **Basic response:** Pneumoconiosis results from specific occupational dust inhalation, classified by the causative substance; specific types include coal worker's pneumoconiosis, silicosis, and asbestosis, each with distinct additional risks.

Value-added response: A value-added response notes that asbestosis carries particularly significant risk of both lung cancer and mesothelioma.

25. **Basic response:** Prevention through occupational exposure control is the most effective strategy given largely irreversible established disease; management of established disease is largely supportive.

Value-added response: A value-added response notes that this reflects the same preventive philosophy emphasised throughout this course wherever a cause is modifiable.

Answers to Pilot Questions [Series 5]

Part 5.1

1. Risk factors include smoking, occupational exposure, and genetic predisposition.
2. Non-small cell lung cancer is more common and less aggressive; small cell is less common and more aggressive.
3. Symptoms include persistent cough, haemoptysis, weight loss, and breathlessness.



4. Superior vena cava obstruction produces facial swelling and distended neck veins from tumour compression.
5. Paraneoplastic syndromes include hypercalcaemia, hyponatraemia, and, in small cell disease, neurological syndromes.

Part 5.2

6. Investigation combines chest imaging, tissue biopsy, and staging investigations.
7. Staging distinguishes disease amenable to curative treatment from disease requiring palliative treatment.
8. Surgical resection is the preferred curative approach for localised, appropriately staged disease.
9. Targeted molecular therapy is directed against specific genetic mutations identified within the tumour.
10. Small cell lung cancer is typically managed with combination chemotherapy, often alongside radiotherapy.

Part 5.3

11. The pathophysiology involves progressive, irreversible fibrosis from abnormal, dysregulated tissue repair.
12. Symptoms include progressive breathlessness on exertion and a dry, non-productive cough.
13. Auscultation reveals fine, bilateral, basal, inspiratory crackles, sometimes described as sounding like Velcro.
14. High-resolution CT demonstrates a characteristic fibrosis pattern, forming the key diagnostic investigation.
15. Management uses antifibrotic medication and supportive care, with a generally guarded prognosis.

Part 5.4

1. Pneumoconiosis results from occupational mineral dust inhalation, requiring a thorough occupational history.
2. Coal worker's pneumoconiosis results from coal dust inhalation, producing a characteristic nodular pattern.
3. Silicosis results from crystalline silica dust exposure, carrying elevated tuberculosis risk.
4. Asbestosis results from asbestos fibre inhalation, carrying elevated lung cancer and mesothelioma risk.
5. Prevention centres on dust control and protective equipment; management of established disease is largely supportive.



References and Attributions [Series 5]

1. Kumar, P., & Clark, M. (2020). Kumar and Clark's Clinical Medicine (10th ed.). Elsevier.
2. National Institute for Health and Care Excellence (2019). Lung Cancer: Diagnosis and Management (NG122). NICE.
3. American Thoracic Society (2018). Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine.
4. Health and Safety Executive (2023). Occupational Lung Disease Statistics. HSE.

Figures, Plates, Tables, and Boxes

1. Figure 5.1: A clinician examining a patient's fingers for clubbing. AI-generated using the prompt: "Create a realistic clinical illustration titled Examining for Finger Clubbing, showing a clinician gently holding a patient's hand and observing the angle of the fingernails from the side, clinical examination room setting. Clean clinical illustration style, no text."
2. Table 5.1: Comparing non-small cell and small cell lung cancer. AI-generated using the prompt: "Create a clean reference table titled Comparing Non-Small Cell and Small Cell Lung Cancer, listing feature, non-small cell lung cancer, and small cell lung cancer. Simple clinical reference table style with outside border."
3. Figure 5.2: A clinician auscultating a patient's lower back for fine, bilateral, basal crackles. AI-generated using the prompt: "Create a realistic clinical illustration titled Auscultating for Basal Crackles, showing a clinician using a stethoscope to listen to a seated patient's lower back, clinical examination room setting. Clean clinical illustration style, no text."
4. Table 5.2: Comparing common specific pneumoconioses. AI-generated using the prompt: "Create a clean reference table titled Comparing Common Specific Pneumoconioses, listing pneumoconiosis, causative dust exposure, and genuinely notable additional risk. Simple clinical reference table style with outside border."

